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                                SUMMARY 
 
Both CD23 and the β2 integrins (also known as CD11/CD18) have very important 
immunological functions, especially during the allergic response where the binding of 
CD23 to β2 integrins contributes to various types of signalling in monocytes which can 
result in drastic sensitivities experienced by some allergic individuals.  
 
CD23, also known as the low affinity receptor for immunoglobulin E or (FcεRII), is a 
type II transmembrane glycoprotein which is synthesized by haematopoietic cells and 
has biological activity in both membrane-bound and freely soluble forms. It acts via a 
number of receptors, including the β2 integrins. 
 
 β2 integrins are specifically found on leukocytes and they play important roles in cell–
cell or cell–matrix adhesion via their ability to bind multiple ligands. These molecules 
occur as heterodimers consisting of an alpha (α) and beta (β) subunit. The α-subunits of 
β2 integrins contain an approximately 200-amino-acid inserted domain or I-domain 
which is implicated in ligand binding function. There are four different types of β2 
integrins, namely CD11a, CD11b, CD11c and CD11d, all dimers with the common beta 
subunit, CD18.  
 
CD23 and CD11/18 are natural ligands of each other; however the interaction site for 
CD23 is unknown. It is postulated that the integrin recognizes a tripeptide motif in a 
small disulfide-bonded loop at the N-terminus of the lectin head region of CD23, which 
is focussed around Arg
172
, Lys
173
 and Cys
174
 (RKC). This study thus focused on the 
interaction between the I-domain of CD11 (b and c) and a recombinant 25kDa construct 
of sCD23. In order to understand the characteristics of ligand binding between the 
relevant proteins of interest, alanine substitutions on the RKC motif of CD23 were 
made via site-directed mutagenesis. Consequently, a recombinant form of the I-domain 
of CD11 (b and c) as well as a wild type (containing the RKC motif) and mutant form 
(containing an AAC motif) of sCD23 were expressed and purified. The CD11 
recombinant proteins were purified via affinity chromatography and the CD23 
 x 
recombinant proteins via gel filtration chromatography. In addition, synthetic (CD23 
derived) peptides, one containing the RKC sequence and the other the AAC sequence, 
were designed and custom synthesized. The synthetic peptides as well as the 
recombinant CD23 proteins were then analyzed for their interaction with the CD11 I-
domain via ELISA. Subsequent ELISA analyses showed that the native sCD23 and the 
RKC peptide were able to bind to the integrin α I-domain whereas the mutant sCD23 
and the corresponding synthetic AAC peptide failed to bind. This interaction was also 
analysed via flow cytometry using differentiated U937 cells, yielding similar results. 
ELISA analyses for the sCD23-CD11b I-domain interaction showed a Kd of 0.36 ± 
0.14 μM whereas the RKC-CD11b I-domain interaction yielded a Kd of 1.75 ± 0.58 
μM. Similarly, the sCD23-CD11c I-domain interaction yielded a Kd of 0.39 ± 0.09 
μM and 1.53 ± 0.72 μM for the RKC-CD11c I-domain interaction.  Peptide inhibitory 
analysis, analysed via ELISA and flow cytometry, reinforced the fact that the RKC 
motif on sCD23 is a prerequisite for ligand binding of the CD11b/c I-domain. 
 
Key words: CD23, RKC-motif, CD11, I-domain 
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1. LITERATURE REVIEW  
  
1.1 Introduction 
The incredible complexity of the human body is perhaps most clearly illustrated by the 
immune system and how it operates. The immune system is a system of biological 
structures and processes within an organism that is composed of many interdependent 
cell types that collectively protect the body from bacterial, parasitic, fungal and viral 
infections as well as the growth of tumour cells. Many of these cell types have 
specialized functions and they all work together to defend the body against disease and 
foreign invaders by identifying and killing pathogens (Linnemeyer, 2008). 
 
Although many of the cells of the immune system are separate from each other, they 
maintain communication via cell contact and molecules secreted by them. On this basis 
the immune system has been compared to the nervous system due to the fact that like 
other body systems, the immune system is only apparent when it goes wrong, which 
consequently can lead to severe infections or even death. An example of such a 
dysfunction is immunodeficiency which can result from infection with the human 
immunodeficiency virus (HIV), which causes AIDS. The immune system can also be 
hypersensitive to a microbe or substance such as pollen, which in itself can cause severe 
tissue damage sometimes also leading to death. Therefore, the immune system needs to 
strike a balance between producing a life-saving response and a response that can cause 
severe tissue damage. This regulation is maintained by cells and molecules of the 
immune system, as well as from without by non-immune cells, tissues and their 
products (Lydard et al., 2004). 
 
The cellular components of the immune system can also be considered as mediators of 
either innate or adaptive immunity. Innate immunity provides the first line of defence 
against infection. It is present at birth and changes little throughout the life of the 
individual. Innate immunity is rapidly activated during the early stages of infection and 
its defensive properties can limit the spread and proliferation of pathogen within the 
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body. However, its efficiency in clearing infection is only moderate and its capabilities 
basically the same upon exposure to the same microbe (Todd & Spickett, 2005). 
 
The recognition characteristics of innate immunity involve recognising chemical 
structures which are characteristic of infectious pathogens and which differ from the 
constituents of the host organism. The structures include various microbial lipids, 
proteins, carbohydrates and nucleic acids which are collectively termed pathogen 
associated molecular patterns (PAMPS). These are bound by secreted proteins (such as 
mannose-binding lectin or C-reactive protein) as well as by cell surface receptors (such 
as toll-like receptors or macrophage mannose receptors). These receptors are called 
pattern recognition receptors (PRRs) and are inflexible in their specificities and 
identical between cells (Todd & Spickett, 2005). 
 
The second line of defence is the adaptive immune system which is brought into action 
while the innate immune system is dealing with the microbe and in most cases 
especially if it‘s unable to remove the invading microbe. A key feature of the adaptive 
immune system is that it shows far more specificity and ‗remembers‘ that a particular 
microbe has previously invaded the body. This results in a more rapid expulsion of the 
microbe upon its second and third time of entry (Lydard et al., 2004).  
 
It is important to note though, that the innate and adaptive immune systems do not 
operate independently since they function as a highly interactive and co-operative 
system. Together, these two systems produce a combined response more effective than 
either branch could produce by itself. An example of such co-operation is seen in the 
encounter between microbes and macrophages. Interactions between receptors on 
macrophages and microbial components generates soluble proteins known as cytokines, 
which are able to stimulate and direct adaptive immune responses which in turn 
facilitate the participation of the adaptive immune system in eliminating the invading 
microbe. Cytokines are growth factor-like molecules which react with receptors on 
various cell types to signal the cell to perform various functions such as the production 
of new factors or to undergo differentiation to a new cell type (Kindt et al., 2007). 
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An effective immune response involves two major groups of cells, namely lymphocytes 
and antigen (Ag) presenting cells. Lymphocytes are immunologically competent, small 
white blood cells that bear the most important responsibility for executing the actions of 
the adaptive immune system. Lymphocytes are one of many types of white blood cells 
which are produced via a process known as haematopoiesis in the bone marrow. After 
leaving the bone marrow, they circulate in the blood and lymphatic systems and reside 
in various lymphoid organs (Kindt et al., 2007). 
 
 All immunocompetent individuals have various distinct lymphocytes and each of these 
cells is specific for different foreign substances or antigen. This specificity arises from 
the fact that each lymphocyte possesses cell surface receptors which are specific for a 
certain antigen. When this particular antigen is introduced into an individual, 
lymphocytes with appropriate receptors seek out and bind the antigen which 
consequently is triggered to proliferate and differentiate into immunity effector cells; all 
of which are specific for the antigen initially triggering the response. These effector 
cells and their products are specifically able to react with the antigen or the cells 
producing it; thereby mediating its elimination (Lydard et al., 2004).  
 
According to Shomon (2002), there are two major populations of lymphocytes, 
specifically: T lymphocytes (T-cells) and B lymphocytes (B-cells). T lymphocytes arise 
in the bone marrow and migrate to the thymus gland to mature. Mature T-cells express 
a unique antigen binding molecule on their membranes known as the T-cell receptor 
(TCR). T-cells consist of three subpopulations, namely: 
 
a) T helper cells (TH), which generally are distinguished by the presence of a particular 
membrane glycoprotein known as CD4 and their function is to help other cells to mount 
an immune response; 
 
b) T cytotoxic cells (TC), which display the membrane glycoprotein CD8 on their 
surface, these cells have the ability to kill virus-infected or allogeneic cells; 
 
 4 
c) T regulatory cells (TREG), these cells carry both CD4 and CD25 on their surface and 
are crucial for the maintenance of immunological tolerance. These T cells inhibit rather 
than activate immune responses, for example, an important function of CD4
+ 
CD25
+
 
TREG cells that arise in the thymus, is to suppress allergic and autoimmune reactions 
(Todd & Spickett, 2005). 
 
Most T cell receptors can recognize only antigen that is bound to cell membrane 
proteins called major histocompatibility complex (MHC) molecules. These molecules 
are genetically diverse glycoproteins found on cell membranes. There are two major 
types of MHC class molecules namely: 
1) Class 1 MHC, which are expressed by nearly all nucleated cells of vertebrate 
species, and 
2) Class 2 MHC which are expressed only by antigen presenting cells (APC). 
(Kindt et al., 2007) 
 
B lymphocytes mature mainly under the influence of the bone marrow. Upon release, 
each expresses a unique antigen binding receptor (or B-cell receptor) on the membrane 
and this BCR is a membrane–bound antibody (Ab) molecule. B-cell antigen receptors 
and secreted antibodies occur as  five immunoglobulin (Ig) classes, designated IgA, 
IgD, IgE, IgG and IgM, respectively (Lydard et al., 2004). These are similar in basic 
structure, consisting of four polypeptide chains connected by disulfide bonds. The 
antibody has two identical light chains and two identical heavy chains (Gould et al., 
2003). 
 
When a naïve B-cell (that is, a B-cell which has not encountered an antigen before) is 
exposed to an antigen which matches its membrane-bound antibody, the consequent 
binding of the antigen to the antibody causes the cell to divide rapidly; resulting in the 
progeny differentiating into memory B-cells and effector B-cells called plasma cells. 
Plasma cells produce the antibody in a secretory form and have little or no membrane-
bound antibody. Very large amounts of antibody are secreted by these plasma cells 
during the time they are active, which is basically just for a few days. Secreted 
antibodies are the major effector molecules of humoral immunity (Kindt et al., 2007). 
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The binding of an antibody to its specific antigen functions to tag the antigen so that it 
can be recognized as being foreign to the host. Cells that can be stimulated by the Ag-
Ab complexes are triggered by surface receptors that are able to bind the Fc region of 
the Ig‘s. When this binding occurs, the Ab confers on these cells their specificity for 
their Ag. The release of mediators by the degranulation of Fc receptor-bearing cells or 
by the synthesis of newly formed bioactive molecules is an essential component of 
many Ab-dependant reactions that are involved in pathogen defence or in allergic 
disorders. In particular, the Ab isotype IgE only exerts its biological function through its 
interaction with cell surface receptors that are specific for its Fc region. The resulting 
dramatic release of a number of potent proinflammatory mediators triggered by Fc 
receptor aggregation is recognized in anaphylaxis and allergic disease (Dessaint et al., 
1990). Figure 1 illustrates such an interaction involving IgE and its receptor proteins 
during an allergic reaction. 
 
There are two types of IgE receptor proteins, namely: 
a) FcεRI, also known as the high affinity IgE receptor, which is responsible for 
immediate hypersensitivity or allergic reactions. The affinity of FcεRI for IgE is 
so high (Ka ~ 1x10
10
 M
-1
) that it is permanently coated with IgE and therefore 
sensitized for rapid activation when exposed to allergen (Sutton et al., 2000). 
Furthermore, the expression of these high affinity receptors is probably up-
regulated by IgE itself (Grimbacher et al., 2002) and; 
 
b) FcεRII, also known as the low affinity IgE receptor or CD23, which is located 
on various cell types such as mast cells, human peripheral blood B-lymphocytes 
and B-lymphoblastoid cell lines amongst others. This is an interesting receptor 
in that besides binding to IgE with a low affinity (Ka ~ 1x10
8
M
-1
); it also acts as 
a B-cell growth factor (Kijimoto-Ochiai, 2002). According to Borland et al.  
(2007), soluble CD23 (sCD23) inhibits apoptosis in pre B-cell lines and through 
an interaction with the leukocyte specific integrins, namely, CD11b-CD18 and 
CD11c-CD18 (receptors which have essential roles in leukocyte trafficking and 
function and which mediate the immune adherence phenomena), it is able to 
stimulate cytokine production by monocytes. It has been determined that 
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engagement of these integrins by natural
 
ligands (particularly, sCD23) and 
certain monoclonal antibodies (mAbs) also generates
 
outside-in cellular 
signalling, which consequently leads to cell activation. In
 
monocytes, this 
activation includes the generation of nitric oxide; the induction of pro-coagulant
 
activity; the up-regulation of cell-surface molecule expression and the 
production of inflammatory cytokines such as tumour necrosis factor-α (TNF-
α), interleukin (IL)-1β, and IL-6 (Rezzonico et al., 2000). However, the 
interaction between CD23 and CD11 has not been characterised well and it 
would be interesting to investigate the exact surface interactions involved when 
CD23 and CD11 bind. 
 
   
 
Figure 1: An illustration of an Immediate hypersensitivity mechanism: a) Allergen-IgE complexes 
are captured by CD23 on the luminal side of the intestinal epithelium and transported into the mucosa 
where they bind to FcεRI  on mast cells and dendritic cells (DCs) thereby causing allergic 
inflammation and local IgE class switching in B-cells and IgE synthesis (step 1). b) IgE synthesized by 
plasma cells in the mucosa are transported by CD23 on the mucosal side of the epithelium into gut 
lumen where they capture allergens and bind to CD23 on the luminal side of epithelium to be delivered 
to mucosa. c) Finally the inflammation caused by allergic reactions mediated by IgE in the mucosa 
damages the intestinal epithelium disrupting the tight junctions between the epithelial cells. Free 
allergens can now pass between cells and bind the IgE- sensitized mast cells and DCs in the mucosa, 
thereby aggravating the food allergy (Gould and Sutton, 2008). 
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IgE may be an important target in treatments for allergy and asthma. Presently, severe 
allergy and asthma is treated with drugs (such as anti-histamines) that relax airway 
smooth muscle and which are also able to clamp down the late stages of inflammation. 
However, these treatments are fairly broad in their action and as a result, can possibly 
inhibit important protective responses and may also have unpleasant side effects. By 
understanding the structure of IgE and its interaction with its receptors, it would be 
possible to develop a new generation of allergy drugs that seek to interfere with the IgE- 
receptor interaction, thereby reducing the drastic sensitivities experienced by some 
allergics.  
 
In the same way, if we are able to determine the exact surface interactions between 
CD23 and CD11, it would be possible to design new treatments that use a similar 
approach to inhibit IgE binding to its receptor. For instance, developing small molecule 
ligands that inhibit the interaction for treatment of chronic inflammatory disease.  
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1.2 The CD23 protein 
1.2.1 The structure of CD23   
Human CD23 is a 45 kDa type II transmembrane glycoprotein consisting of 321 amino 
acids. This protein is encoded by a single-copy gene that contains 11 exons and spans 
13 kb found on chromosome 19 (Conrad, 1990). The protein is found on activated 
macrophages, monocytes, mature B cells, oesinophils, platelets and follicular dendritic 
cells. It is an unique Fc (crystallisable fragment) receptor in that it belongs to the C-type 
lectin-like domain superfamily (Wurzburg et al., 2006) and consists of an extracellular 
C-terminus and cytoplasmic N-terminus as compared to all the other Fc receptors, 
which are type I membrane proteins belonging to the immunoglobulin superfamily 
(Kijimoto-Ochiai, 2002). 
 
A ―stalk‖ region of CD23 is located between the lectin domain and the 
transmembrane regions. The stalk of human CD23 has 3 amino acid repeats. There is 
also a periodic heptad repeat containing a hydrophobic amino acid (customarily 
leucine) in the stalk, which is characteristic of a leucine zipper motif (Kilmon et al., 
2001). Like several C-type lectins, CD23 self-associates through its extracellular 
sequence by the formation of an α-helical coiled-coil stalk (Beavil et al., 1992). 
Membrane CD23 has been shown to form trimers with the three lectin domains held 
together at the end of the 15 nm stalk. 
 
Human CD23 is cleaved by endogenous proteases, initially at a specific location near 
the base of the stalk, to release a fragment of 37 kDa (Letellier et al., 1989). The 
enzyme responsible for this cleavage appears to be the metalloproteinase ADAM10 
(Lemieux et al., 2007). Other enzymes cleave the 37 kDa fragments further up the stalk 
and at a site within the tail to produce progressively smaller fragments containing the 
lectin head and a portion of the tail (Letellier et al., 1989). There are four cleavage sites 
on human CD23 which release soluble fragments of 16, 25, 27-29, 33 and 37 kDa in 
size, respectively (Daniels et al., 2005). Furthermore, the allergen responsible for dust 
mite allergy, known as Der p I protease from Dermatophagoides pteronyssinus, is 
known to cleave sCD23 from the cell surface as well (Borland et al., 2007).  
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In addition to the soluble fragments, there are also two forms of CD23 that can be 
expressed in the cell membrane, namely CD23a and CD23b (McCloskey et al., 2007). 
CD23a is present on follicular cells whereas CD23b is expressed on monocytes, T cells, 
macrophages, eosinophils and Langerhans cells. These two structures differ by six or 
seven amino acids at their terminal cytoplasmic regions and display different modes of 
cell regulation, function and expression (Kikutani et al., 1989).  
 
Figure 2 A and B (Hibbert et al., 2005) illustrates a model for the trimer formed by 
full-length CD23 and Figure 2 C (Kijimoto-Ochiai, 2002) shows the two dimensional 
depiction of the structure of CD23 where six main structural features are illustrated. 
These are the C-type lectin domain, the a and b forms of the protein that differ in their 
amino acid sequences at the N-terminal region, the leucine-zipper structure, the protease 
cleavage sites, the reverse-RGD sequence near the C-terminus and the ―RGD-binding 
inhibition peptide‖ at the root of the N-linked carbohydrate chain. With regards to this 
particular figure, of particular note is the inverted RGD sequence (a cell adhesion 
sequence recognized by integrin ligands), which is read from the C-terminus and not the 
N-terminus. The function of this sequence in CD23 is not known though.  Human 
CD23 also has a reversed RGD-binding inhibitory peptide around the N-sugar chain. 
The function that this peptide performs is also unknown (Kijimoto-Ochiai, 2002).    
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C 
 
 
Figure 2: Structural features of sCD23: A) An overhead view of the postulated CD23 trimer is shown. 
Residues that show concentration-dependent chemical shift changes in NMR are displayed in a surface 
representation and for each monomer, a backbone ribbon cartoon is shown in gray. The surfaces are 
coloured according to electrostatic charge, representing the electrostatic complementarity of the two 
sites. Side chains for residues that are part of the ligand interaction site for immunoglobulin E (IgE) are 
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shown and coloured in green. B) Cartoon representations (top and side views) demonstrating the 
overall architecture of the trimer and the ligand binding sites. The two oligomerization sites are 
coloured blue and red, respectively, the CD21 binding site is cyan, the IgE interaction site is green, and 
the calcium binding site is yellow. The front two molecules of the trimer are semitransparent (Hibbert 
et al., 2005). C) Schematic structure of the CD23 protein.  The figure illustrates the lectin head (1); the 2 
forms of CD23 (2); the leucine zipper sequence (3); the protease cleavage sites for sCD23 (4); the reverse 
RGD sequence (5) and lastly the RGD-binding inhibition peptide (6). The sizes of the released soluble 
molecules are indicated, arrows indicate β-sheet, single lines indicate loops and double lines indicate α 
helix (Kijimoto-Ochiai, 2002). 
 
1.2.2 Functions of CD23 
1.2.2.1 The functions of soluble CD23 
sCD23 has the profile of a multi-functional cytokine (Delespesse et al., 1992) and in 
synergy with IL-1, sCD23 is a differentiating factor for myeloid cell precursors, a subset 
of germinal centre B cells, named centrocytes, and early thymocytes (Mossalayi et al., 
1997). Most activities of sCD23 are pleiotropic and IgE independent. sCD23 promotes 
differentiation of germinal centre (GC) B cells into plasma cells in vitro, most likely 
interacting with CD21 and thus extending their lifetime and capacity to proliferate, until 
they receive further signals. Other activities of sCD23 also include co-stimulation with 
IL-1 of prothymocyte maturation, increasing histamine release by human basophils 
and myeloid precursor cell growth (Gould et al., 2003).  Furthermore, in the presence of 
IL-1α, sCD23 prevents apoptosis of centrocytes awarding them the phenotype of 
plasmablasts. sCD23 is also able to stimulate TNF-α and IL-1α/β production by 
monocytes through an interaction with CD11b/c and αVβ3 integrins (Borland et al., 
2007). 
 
1.2.2.2 The functions of membrane CD23 
The functions of membrane CD23 vary according to the cell type on which it is 
expressed.  Membrane CD23 performs a variety of functions, including IgE antibody-
dependent presentation of antigens in murine and human B cells, feedback inhibition of 
IgE synthesis in murine B cells and IgE antibody-dependent killing of tumour cells by 
human monocytes (McCloskey et al., 2007).   
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CD23a located on B-cells, arbitrates endocytosis, whereas CD23b on monocytes 
mediates phagocytosis. The function of CD23 on B-cells is the enhancement of IgE-
dependent antigen presentation to T cells and in order for this to occur, CD23 must bind 
Ag-IgE complexes, internalize these complexes and then transport them to 
compartments of the endosomal network containing proteolytic enzymes and MHC II 
proteins. After proteolysis of the antigen, restricted peptides are loaded onto MHC II 
proteins and returned to cell surfaces for T cell presentation (Karagiannis et al., 2001). 
 
CD23b-mediated functions are dependent on CD23 cross-linking by IgE immune 
complexes. CD23 on macrophages, eosinophils and platelets mediates IgE-dependent 
cytotoxicity and promotes the phagocytosis of IgE-coated particles (Conrad, 1990). In 
addition, CD23 crosslinking in monocytes induces the activation of tyrosine kinase, 
which in turn activates IκB kinase, which phosphorylates IκBα, resulting in its 
degradation and therefore NF-κB activation and gene transcription (Ten et al., 1999). 
According to Richards and Katz (1991), CD23 on monocytes and macrophages  
controls the IgE-dependent inflammatory processes, especially during allergic 
manifestations where binding of IgE to CD23 on monocytes induces the release of 
interleukin 13 (IL-13) and TNFα. CD23 also interacts with integrins CD11b/CD18 
and CD11c/CD18 on monocytes which in turn stimulates the production of pro-
inflammatory mediators IL-1ß, TNFα, interleukin 6 (IL-6) and nitrite oxidative 
products (Rezzonico et al., 2000). 
 
1.2.3 Regulation of CD23 activity 
IL-4 is the strongest inducer of CD23 expression on most cell types including normal 
B cells and monocytes. However, CD23 may also be up-regulated by IL-2 on 
activated normal B cells as well as on leukaemic B lymphocytes from patients 
suffering from chronic lymphocytic leukaemia (B-CLL); nonetheless, the effect of IL-
2 is much less distinct than that of IL-4. CD23 may be up- or down-regulated by IFNγ 
depending upon the cell type on which it is expressed. IFNγ acts as a powerful 
inhibitor of CD23 expression on IL-4-stimulated normal B cells, allergen-stimulated 
T cells of allergic patients and Burkett‘s lymphoma cell lines. On the contrary, IFNγ 
up-regulates CD23 on platelets, the eosinophil EOL3 cell line, Langerhans cells and 
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the U937 monocytic cell line. Interestingly, IFNγ does not affect the constitutive 
CD23 expression on human T lymphocytic leukaemia virus 1-transformed or on the 
majority of Epstein-Barr Virus (EBV)-transformed cells. Quite the opposite of IFNγ, 
IFNα inhibits IL-4-induced CD23 on normal B cells and on monocytes. Agents such 
as prostaglandin E2, corticosteroids and lipid mediators can also control CD23 
expression (Fournier et al., 1992). 
 
1.2.4 CD23 ligand interactions 
CD23 interacts with multiple ligands, the interactions of which control important 
aspects of immune regulation. As a receptor for IgE, CD23 plays a role in antigen-
presentation and macrophage activation. As a soluble molecule shed from the cell 
surface, CD23 can act as a cytokine or as an adhesion molecule which can interact 
with CD21, the β2 integrins (CD11b and CD11c) and the vitronectin receptor, also 
known as αVβ3 (Hermann et al., 1999). It has also been suggested that CD23 has 
additional as yet unidentified ligands, for example, proteins that may interact with 
CD23‘s reverse RGD sequence (Sutton and Gould, 1993). Furthermore, according to 
Bajorath and Arrufo (1996), CD23 explicitly interacts in a calcium-dependent, ―lectin-
like mode‘‘ with carbohydrate moieties expressed on CD21 and CD11b/c, but also in 
a ―lectin-unlike mode‘‘ with protein epitopes on IgE. 
 
1.2.4.1 CD23 and IgE 
The chief effector function of IgE is believed to be sensitization of mast cells for 
allergen triggering of an allergic response. This serves as protection against parasite 
infections, but confers the risk of allergic disease in susceptible individuals. The lower 
affinity of IgE for CD23 (KD ~10
-7– 10-8 M) than for FcεRI (KD ~ 10
-10
 – 10-11 M), 
together with feedback regulation of IgE synthesis by IgE, guarantees that the mast 
cells remain sensitized once excess IgE has been eliminated (Hibbert et al., 2005).  
 
Incidentally, as shown in Figure 1, which illustrates a schematic representation of 
early sensitization of a mast cell, we see how the CD23-IgE interaction is accountable 
for the protective functions of phagocytic clearance of antigen and cellular 
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cytotoxicity, although it is also associated with delayed allergic reactions (Beavil et 
al., 1992). 
 
IgE interacts with human CD23 and its 37, 33 and 25 kDa soluble fragments where 
CD23 binds IgE in an unusual, non-lectin-like mode which requires calcium but not 
carbohydrates (Wurzburg et al., 2006). The glycosylation of CD23 is not necessary for 
IgE binding because the truncated products of human CD23 have no N-glycosylation 
sites. As shown in figure 3, the peptide region that interacts with IgE has been shown to 
be the lectin domain of CD23, supported by evidence that binding is calcium 
dependent. Mutations in the lectin domain of CD23 change its IgE binding ability, 
further supporting the theory that the interaction site with IgE is in the lectin cassette 
(Hibbert et al., 2005). 
 
  
 
Figure 3: Structures of sCD23 indicating different binding domains: A) A schematic representation of 
the structure of CD23 illustrating the three C-type lectin domain ‗heads‘, the extracellular trimeric α-
helical coiled-coil ‗stalk‘ and the C-terminal ‗tails‘. B) A three dimensional representation of one of the 
CD23 head domain regions, indicating binding regions for IgE-Fc, CD21 (situated adjacent to the C-
terminal tail) and the αvβ5–integrins, situated in the N-terminal region close to the connection to the stalk.  
The NMR structure  is illustrated in blue [Protein Data Bank (PDB) ID: 1T8D] ) and the X-ray crystal 
structure  is shown in red [PDB ID: 2H2T] – but only the regions where the two structures differ most are 
superimposed. The single Ca
2+
 ion observed is shown as a sphere in its respective colour [Gould & Sutton 
(2008); Hibbert et al. (2005) and Wurzburg et al. (2006)]. 
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CD23 binds oligosaccharide-free IgE peptides including enzymatically deglycosylated 
IgE. It has also been shown that the interaction between IgE and CD23 isolated from 
murine B-cells is not inhibited by high concentration of mono- or disaccharides. 
Therefore, despite the localization of the IgE-binding epitope within the lectin domain 
of CD23, carbohydrate does not appear to be required for binding. Monoclonal 
antibody epitope mapping studies of the CD23 binding site on IgE have shown that 
both human and murine CD23 interact with the Cε3 domain of their respective IgE 
ligands (Sayers et al., 2004). 
 
CD23 binds IgE with both high and low affinity. However, the increase in surface 
CD23 does not lead to an increase in IgE binding. This dual affinity was explained by 
Gould et al. (2003) to be related to the oligomerization of CD23. According to this 
model, low affinity binding occurs when one molecule of IgE is bound to one CD23 
molecule, and high affinity binding occurs when a molecule of IgE is bound by 
multiple CD23 receptors at the same time. 
 
Paradoxically, as shown in figure 4, CD23 engages in both the up and down 
regulation of IgE production, thus establishing a two-way switch in IgE homeostasis. 
These opposing activities of CD23 in IgE regulation are considered to be 
characteristics of the soluble and  membrane forms of CD23, where soluble CD23 
enhances IgE synthesis upon binding to CD21 and when IgE binds to membrane 
CD23, further IgE synthesis is suppressed (Hibbert et al., 2005). 
 
When CD23 is not engaged by IgE, it is cleaved to release soluble CD23 fragments 
that upregulate IgE synthesis in an autocrine fashion. The binding of IgE to CD23 
protects the receptor against proteolytic cleavage, but also allows membrane CD23 to 
deliver a negative IgE regulatory signal to the B-lymphocyte (Schulz et al., 1997). 
The protective effect of IgE on initial cleavage of CD23 (through the binding of the 
lectin domain), results from alleviating the integrity of the coiled coil structure which 
contains the cleavage site. Unraveling of the coiled coil domain via the leucine zipper 
region of CD23 when IgE is not bound results in cleavage of the receptor. It is 
considered that any exogenous agent that is able to interact with the leucine zipper 
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domain of CD23 could possibly disrupt the IgE inhibitory mechanism thereby leading 
to enhanced IgE synthesis. Furthermore, according to Tsicopoulos and Joseph (2000), 
sCD23 fragments larger than 25 kDa that retain a part of the stalk region promote 
continuing IgE production by at least two mechanisms, namely: 
a) sCD23 directly stimulates IgE production  possibly through triggering of CD21;  
b) sCD23 by its ability to trap IgE in the medium prevents negative feedback through 
membrane CD23. 
 
 
 
Figure 4: Up and down regulation of IgE by CD23.  On the left hand side IgE synthesis is down 
regulated due to the co-cross-linking of membrane CD23 (mCD23) and membrane IgE (mIgE) by an 
allergen–IgE complex whereas on the right hand side, trimeric soluble CD23 co-cross-linking of 
membrane IgE and CD21 leads to up-regulation. IgE binding to membrane CD23 also protects the 
latter against proteolysis and prevents formation of soluble CD23 (Hibbert et al., 2005). 
 
The opposing activities of CD23 in IgE regulation are thought to be properties of the 
soluble and membrane forms. Soluble CD23 enhances IgE synthesis on binding to 
CD21 (Aubry et al., 1992). When IgE binds to membrane CD23, further IgE synthesis 
is suppressed; in CD23-deficient mice, the level of circulating IgE is increased by 
orders of magnitude (Gould et al., 2003). The balance between the two forms of 
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CD23 may accordingly be expected to regulate the level of IgE synthesis (Hibbert et 
al., 2005). 
 
1.2.4.2 CD23 and CD21 
The human complement receptor type 2 (known as CR2 or CD21), is a cell surface 
protein that is highly expressed on B lymphocytes and follicular dendritic cells (Prota 
et al., 2002). CR2 is an approximately 145 kDa type I transmembrane protein 
encompassing 15 or 16 short consensus repeats (SCRs) followed by a 28-amino acid 
transmembrane domain and a relatively short 34-amino acid intracytoplasmic tail 
(Fujisaku et al., 1989). SCRs, also known as complement control protein (CCP) 
repeats, are 60- to 70-amino acid-long protein modules that each contain two disulfide 
bonds and comprise the majority of the structures of CR2 and other members of the 
extended gene family called the regulators of complement activation (RCA) of which 
CD21 is a member (Kirkitadze and Barlow, 2001). The 15 and 16 SCR forms of CR2 
vary by alternative splicing of a single exon (Fujisaku et al., 1989).  
 
Human CD21 is unique in that it has at least four classes of ligands. These include the 
progressively cleaved C3 (complement protein 3) activation fragments (iC3b, C3d 
and C3g), Epstein - Barr virus (EBV) via the surface protein gp350/220, IFN-α and of 
course, the immunomodulatory protein CD23 (Aubrey et al., 1994). C3 activation 
fragments are covalently attached to antigen or to immune complexes following 
complement activation, thus allowing for high-affinity interactions of C3-bound 
targets with CD21 (Holers, 2005). 
 
sCD21 and sCD23 form biologically active complexes (Fremeaux-Bacchi et al., 
1998). This interaction requires glycosylation of CD21. In addition, this interaction 
involves the C-type lectin domain of CD23 and these two molecules are regarded as a 
pair of adhesion molecules (White et al., 1997). CD23 binds to domains 1–2 (SCR 1-2) 
and domains 5–8 (SCR 5-8) via protein–protein and protein–carbohydrate 
interactions, respectively (Aubrey et al., 1994). The interactions of CD23 with IgE 
and CD21 are pivotal in IgE regulation (as seen in figure 4 and discussed in section 
1.2.4.1), whereby CD21 seems to mediate two important cytokine activities ascribed 
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to CD23; which is namely the upregulation of IgE synthesis and the rescue of 
germinal center B-cells from apoptosis (Sutton and Gould, 1993). 
 
1.2.4.3 CD23 and the β2 integrins 
On monocytes, sCD23 binds the β2 integrins, CD11b-CD18 (αMβ2) and CD11c-CD18 
(αXβ2), and to the αVβ3 vitronectin receptor (VnR) isoform promoting pro-
inflammatory cytokine synthesis. However, the protein domains responsible for the 
CD23-integrin interactions are not defined (Arnaout, 2009). β2 integrins are restricted to 
cells of the immune system and have therefore also been referred to as leukocyte 
integrins or leukocyte adhesion molecules. It is apparent that among the different 
classes of adhesion molecules, the integrin family of adhesion receptors is unique in 
the sense that they constitute a large group of widely distributed receptors, they are 
unusually complex in structure and function, and most importantly their activities are 
strictly regulated from the inside of the cell (Gahmberg et al., 2009). We delve deeper 
on the topic of the β2 integrins in section 1.3.1. 
 
1.2.5 Biological importance of CD23 
CD23 is implicated in the pathogenesis of allergic and autoimmune disease. In general, 
CD23 fragments are normally found in the circulation of healthy human subjects, 
though, elevated concentrations of circulating soluble fragments are commonly 
associated with inflammatory or lympho-proliferative diseases, such as rheumatoid 
arthritis, asthma, and chronic lymphoblastic leukemia, also known as CLL 
(Mavromatis and Cheson, 2004). In addition, elevated levels of soluble CD23 are 
present in patients suffering from Sjögren‘s syndrome and systemic lupus 
erythematosus amongst others. Furthermore, its expression in patients suffering from 
allergic disease is also greatly increased (McCloskey et al., 2007). It is suggested that 
sCD23 levels may also act as a prognostic indicator of B-CLL. Moreover, chimeric 
protein studies of murine CD23 have shown that sCD23 proteins which have retained 
a portion of the stalk region may possibly act as alternative immune therapeutics that 
can block FcεRIα-IgE binding as well as IgE production by B-lymphocytes whereas 
at the same time, anti-CD23 antibodies decrease IgE synthesis. Despite this fact, the 
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pleiotropic functions of CD23 warn against premature use of such therapy (Daniels et 
al., 2005). 
 
1.3 Integrins 
Integrins are heterodimeric transmembrane glycoproteins that mediate attachment 
between cells and the tissues surrounding it (Humphries et al., 2006). Integrins have 
been found in all animals investigated ranging from metazoa and sponges to mammals 
and have been extensively studied in humans (Zhang, 1999). Integrins contain large 
alpha (α) and small beta (β) subunits, where both subunits are type I transmembrane 
proteins which form a noncovalent association with each other (Springer, 2002). 
Integrins also contain binding sites for divalent cations such as calcium (Ca
2+
) and 
magnesium (Mg
2+
) which has been found to be necessary for their adhesive function. In 
mammals, 18 (α) and 8 (β) subunits have been discovered and to date 24 different α - β 
combinations have been identified at the protein level (Humphries et al., 2006), forming 
the integrin superfamily (Figure 5). 
 
 
   
Figure 5: The integrin superfamily.  The integrins can be subdivided according to their β chains but 
note that some α chains can join with several β chains. 24 different integrins are present in humans 
(Gahmberg et al., 2009). 
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1.3.1 β2 integrins 
According to Xia and Ross (1999), and Choi and Nham (2002), β2 integrins are 
exclusively expressed on leukocytes and include four different heterodimers namely: 
a) CD11a/CD18, also known as lymphocyte function associated antigen 1 (LFA-1 or 
αLβ2), which is the predominant β2 integrin, 
b) CD11b/CD18, also known as macrophage–1 antigen (MAC-1 or αMβ2), which is 
expressed in small subsets of B and T cells, mature myeloid cells and natural killer 
(NK) cells, 
c) CD11c/CD18, also known as p150, 95 or αXβ2, is found on monocytes, neutrophils 
and macrophages and specific activated B lymphocyte populations, and  
d) CD11d/CD18, also known as αDβ2, is expressed predominantly on myelomonocytic 
cells.  
 
1.3.1.1 β2 integrin structure 
The integrin β2 subunit CD18 forms heterodimers with each of four CD11 α-subunits 
— CD11a (αL), CD11b (αM), CD11c (αX) and CD11d (αD) — to form a subclass of 
integrins known as β2 integrins, or CD11–CD18 (Arnaout, 1990). The human CD18 
gene, ITGB2, is located on chromosome 21q22.3 and encodes a 95 kDa glycoprotein 
(Kishimoto et al., 1987). The respective human CD11 genes (ITGAL, ITGAM, ITGAX 
and ITGAD) are located on chromosome 16p11.2 and encode glycoproteins of 180, 
160, 150 and 145 kDa, respectively (Arnaout, 2009). 
 
Subunits L, M, X, and D share two important characteristics in the extracellular region 
of the molecule, namely: 
a) A 200 amino acid inserted domain known as the ‗I domain‘ (Choi and Nham, 2002), 
which is implicated in ligand binding (Nham, 1999) and 
b) A reputed divalent cation binding region (Diamond et al., 1993). 
 
Figure 6 illustrates the basic structure of integrins and their extracellular domains 
(Gahmberg et al., 2009) 
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Figure 6: Structure of an integrin and its extracellular domain: A) Schematic drawing of the LFA-1 
integrin. It should be noted that the α I-domain is within the β-propeller, and the β I-like domain within 
the hybrid domain. The positions of the Mg+ (★) and Ca+ (★) binding sites are also indicated. B) On 
the left the ligand binding sites are directed towards the membrane and on the right, the stretched out 
intermediate affinity form is shown (Gahmberg et al., 2009). 
 
A) 
B) 
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With regards to figure 6 (B), the ectodomain of β2 integrins looks like a ―head‖ 
mounted above 2 ―legs‖, one from each subunit. The integrin head consists of an N-
terminal, seven bladed beta propeller domain from the α subunit that is linked through a 
predominantly hydrophobic interface with a von Willebrand factor type A domain, 
termed βA domain from CD18. The α subunit propeller contains a βA-like domain, 
termed ―I domain‖ which is situated between blades 2 and 3 of the G protein-like 
seven-bladed β-propeller domain (Springer, 1997). The upper and lower leg segments 
from the α subunit comprise an immunoglobulin (Ig) – like thigh domain and two large 
beta sandwich domains. The lower leg segment of CD18 consists of four epidermal 
growth factor (EGF) - like domains with a novel beta tail domain and the upper leg 
segment comprises an N-terminal plexin – semaphorin –integrin (PSI) domain and a 
split Ig - like hybrid domain flanking the βA domain. The helical transmembrane 
segment of each subunit ends with cytoplasmic tails (Arnaout, 2009). 
 
According to Arnaout (2009), it is suggested that the I-domain is the major binding site 
in β2 integrins. Moreover, the I-domain contains a metal ion dependent adhesion site 
(MIDAS) at the top of the domain where the ligand is bound and surrounding this 
MIDAS, there are five exposed loops which undergo conformational changes to bind 
the respective ligands when activated (Humphries et al., 2006). The I-domain can exist 
in two different conformations: an ―open‖ (high affinity) and a ―closed‖ (low affinity) 
conformation. An essential feature is the presence of the ―MIDAS‖, which 
coordinates divalent metal cations required for the integrin high affinity state (Qu and 
Leahy, 1996). The I-domain recognizes specific sequence motifs which harbour critical 
solvent expressed acidic residues, the latter of which binds in a divalent cation - 
dependent manner via this MIDAS motif (Arnaout, 2009). 
 
Another interesting structural feature is the β chain ―I-like‖ domain. Crystallographic 
studies show that in integrins which lack the α chain I-domain, the β I-like domain is 
the primary ligand binding site. It contains three metal binding sites, namely, the 
MIDAS, the ADMIDAS (adjacent to the MIDAS), and the LIMBS (Ligand Induced 
Metal Binding Site). In the physiologic low affinity state, all three metal binding sites 
are occupied: the MIDAS by a magnesium ion, while the other two metal binding 
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sites can be occupied by calcium ions (Zhu et al., 2008). However, this result is in 
contrast with previous studies that showed only one metal present in the absence of 
ligand (Zhiong et al., 2002). The magnesium ion at MIDAS directly coordinates the 
aspartic acid residue of the argine-glycine-aspartate (RGD) ligands (the major binding 
motif in many integrin ligands), which otherwise would be electrostatically repelled 
by the anionic residues of the MIDAS itself (Zhu et al., 2008). In addition to its 
known regulatory role, the ADMIDAS calcium ion can also be involved in ligand 
binding (Springer et al., 2008). 
 
1.3.1.2 β2 integrin function 
Although the main functions of integrins include the attachment of cells to the 
extracellular matrix (ECM) and signalling molecules in both directions across the 
plasma membrane (Gahmberg et al., 2009), they also play an important role in the 
regulation of various cellular activities such as immune patrolling, cell migration, 
growth and differentiation. In general, the leukocyte integrins mediate several leukocyte 
activities such as chemotaxis, migration, phagocytosis, cell adhesion and respiratory 
burst (Humphries et al., 2006). In particular, it has been found that: 
 
a) CD11a is crucial for many functions of the immune system where it is involved in 
the control of cell differentiation and proliferation, the interaction between T-cells and 
antigen presenting cells, the regulation of T-cell effector functions and a process known 
as extravasation which involves the adhesion of cells to post-capillary high endothelial 
venules or to activated endothelium at sites of inflammation (Kellersch and Kolanus, 
2006). 
 
b) It has been shown that CD11b is responsible for neutrophil homotypic adhesion; 
myeloid cell adhesion to substrates coated with serum, chemotaxis, transmigration 
across the epithelium or endothelium and also the binding and phagocytosis of 
particles which have been opsonized (Diamond et al., 1993). Furthermore, according 
to Xia and Ross (2010) it has been determined that as an adhesion molecule, CD11b 
mediates the diapedesis of leukocytes via the creation of a high affinity binding site 
for intercellular-leukocyte adhesion molecules (ICAM-1). On the other hand, it can 
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also function as a receptor for the opsonic fragment of C3 (iC3b) where it mediates 
the phagocytosis of immune complexes opsonized with iC3b and degranulation in 
response to micro-organisms. Ligand engagement by CD11b instigates a variety of 
intracellular signalling events, which consequently controls many leukocyte reactions, 
including the expression of procoagulant activity, aggregation and as mentioned 
before, phagocytosis (Plow and Zhang, 1997). CD11b also acts as a pattern recognition 
receptor of innate immunity by interacting with lipopolysaccharides (LPS) and other 
microbial glycoconjugates. This is done both in collaboration with CD14 as well as 
autonomously. CD14 serves as the major signal-transducing receptor in this relationship 
while CD11b is the main LPS-binding molecule. In spite of this, there is a CD14-
independent pathway of LPS-stimulation that is mediated by CD11b. This pathway 
leads to up-regulation of inducible nitric oxide synthase (iNOS) and increased nitric 
oxide production (Ehlers, 2000). 
  
c) CD11c is said to play an important role in phagocytosis; chemotaxis and is 
implicated in the adhesion of monocytes and neutrophils to endothelium and other 
substrates (Diamond et al., 1993). According to Noti and Reinemann (1995), CD11c 
mediates the adherence of TNF-α-stimulated neutrophils and activated B-cells to 
fibrinogen and it also stimulates respiratory burst in neutrophils. Its expression on 
cytotoxic cells is shown to be essential for target cell destruction. Nevertheless, 
compared to CD11a and CD11b, CD11c is less well functionally characterized. 
 
1.3.1.3 β2 integrin ligand interactions 
Integrins bind to a considerable number of cell membrane proteins and extracellular 
matrix molecules. In general, the β2 integrin ectodomains interact with more than 30 
extracellular ligands where the best characterised integrin ligands are the Ig 
superfamily members, including vascular cell adhesion molecule (VCAM-1) and the 
ICAMs. The leukocyte-specific CD11/CD18 integrins bind to ICAMs, especially 
CD11a, which mediates the interaction with ICAM-1, ICAM-2, and ICAM-3 
(Yalamanchili et al., 2000). CD11b also binds to ICAM-1, as
 
well as to several soluble 
ligands, including the complement fragment
 
iC3b, fibrinogen, coagulation factor X, and 
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LPS (Diamond et al., 1993).  CD11c binds many ligands such as collagen type 1, 
iC3b, fibrinogen, LPS and possibly ICAM-1 (Nham, 1999 and Arnaout, 2009). 
Nonetheless, compared with CD11a and CD11b, the ligands and functional role of 
CD11c is less well functionally characterized but appear to be similar
 
to those of 
CD11b (Rezzonico et al., 2000). Furthermore, according to Lecoanet-Henchoz (1995) it 
has been reported that CD11b/CD18 and
 
CD11c/CD18 can exhibit an additional 
adhesive function because
 
of their ability to bind the low affinity receptor for IgE, 
CD23. 
 
The short cytoplasmic tail of CD18 interacts with several proteins, including: 
a) Cytoskeletal proteins such as kindlin 3, talin, filamin and α-actinin (Arnaout, 
2009), 
b)  Signalling proteins such as cytohesin-1, focal adhesion kinase and protein 
kinase D (Arnaout, 2009) and 
c) Adaptor proteins such as JAB-1 and 14-3-3   proteins (Gahmberg et al., 2009). 
 
It should be noted that generally, some integrins tend to show a high specificity for 
certain ligands whereas others tend to bind several different types of ligands. According 
to Gahmberg et al. (2009), a key observation was the identification of a RGD motif 
identified in fibronectin and various other proteins which acts as a common recognition 
site for integrins. However, integrins are known to bind to proteins via other peptide 
motifs which usually results in improvement of the outcome of occupation of the RGD 
site (Borland et al., 2007). Furthermore, according to Borland et al., (2007), it was 
found that CD23 derived arginine-lysine-cysteine (RKC) containing peptides interacted 
specifically with the β chains of the αV integrin family and not with the α-chain; 
although this is understandable considering the fact that αV-integrins do not contain an 
I-domain in their α-chains. Furthermore, Western blotting data further demonstrate that 
the αV integrins have a second ligand binding site that is separate from the RGD-
binding site. The data also suggested that free β chains might be used in in-vitro assays 
for ligands interacting with this second integrin binding site or for screening small 
molecules that might inhibit the interaction of RKC-containing probe peptides with 
isolated β chains.  
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1.3.1.4 Regulation of activity of β2 integrins 
β2 integrins exist in an inactive bent conformation, rendering circulating leukocytes 
nonadhesive under normal conditions. However, in response to agonists such as 
chemokines and growth factors, a process called 'inside-out' activation occurs where β2 
integrins switch within seconds from a low-affinity to a high-affinity conformation 
(Hynes, 2002). Binding of kindlin 3 and or the talin head to the membrane-distal and 
membrane-proximal NPXF/Y motifs, respectively, of the CD18 cytoplasmic tail 
initiates this inside-out activation (Moser et al., 2009).  The activation causes the α–β 
cytoplasmic and transmembrane interactions that maintain the bent integrin in the 
inactive state to be disrupted, which in turn results in the release of local constraints on 
the βA domain, which is close to the plasma membrane in the bent conformation, 
leading to its activation (Arnaout et al., 2005). Binding of extrinsic ligands then 
transmits information into the cell, a process called 'outside-in' signaling. This process 
is mediated through conformational changes in the integrin that include complete 
separation of the transmembrane segments, inviting new interactions of the cytoplasmic 
tails with signaling, adaptor and cytoskeletal proteins, leading to integrin clustering and 
formation of dynamic macromolecular complexes that mediate the diverse adhesion-
dependent cellular functions of integrins (Arnaout et al., 2007).  Figure 7 illustrates a 
partially hypothetical view of LFA-1 activation. 
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Figure 7. A schematic and partially hypothetical view of LFA-1 activation. The ligand binding site 
is closed when filamin is bound to the integrin in the resting state (left).  Upon activation through the T 
cell receptor, activated calpain may cleave talin, which results in binding of the talin head to the 
integrin cytoplasmic tails and the consequent separation of the integrin chains. Phosphorylation of β2 
(Thr-758) results in 14-3-3 binding, displacement of talin and the activation of Rac1/Cdc42, which 
results in integrin clustering because the actin cytoskeleton is affected. The integrin here is shown in 
extended forms (Gahmberg et al., 2009). 
 
The illustration depicted in figure 7, gives an indication of how signals that regulate 
ligand binding are transmitted in integrins, where large-scale restructuring in the 
quaternary organization of extracellular domains is linked to specific conformational 
changes within domains. 
 
1.3.1.5 Biological importance of β2 integrins  
The biological importance of β2 integrins is highlighted in patients with a CD18 
mutation or deficiency. Patients with this condition, known as leukocyte adhesion 
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deficiency I (LAD-1) exhibit increased susceptibility to infections from certain bacterial 
or fungal infections of the skin, upper and lower gastrointestinal and respiratory tracts. 
They also develop peripheral blood neutrophilia, impaired wound healing and pus 
formation (Mayadas, 2005). According to Simonsen et al. (2006), the importance
 
of 
CD11a for T cell function is suggested in vivo by the considerable deficiency in 
adaptive immunity which was observed in β2 subunit-deficient mice. The contribution 
of CD11b to the inflammatory response is regarded as highly important, especially in 
vivo, since excessive activation of CD11b can have adverse effects such as 
autoimmune diseases, tissue destruction and ischemia-reperfusion injury (Plow and 
Zhang, 1997). CD11c plays an important role in the progression of the inflammatory 
events leading to demyelination and paralysis during experimental autoimmune 
encephalomyelitis (EAE) and it is believed that β2 integrin proteins are involved in 
demyelinating diseases (Bullard et al., 2007). 
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2. OBJECTIVES OF THIS STUDY 
 
Both CD23 and the β2 integrins have very important immunological functions, 
especially during the allergic response where the binding of CD23 to β2 integrins 
contributes to various types of signalling in monocytes which can result in drastic 
sensitivities experienced by some allergic individuals.  
 
Since the molecular structure of the CD11b/c receptor that enables it to interact with 
many unrelated ligands, as well as the physiological functions of these interactions, is 
not yet clear and due to the important role that CD11 and CD23 play in the immune 
response, it would be interesting to investigate the interaction surface between the two. 
Furthermore, if these exact surface interactions are known, then it would be possible to 
develop small molecule ligands that will inhibit the interaction for treatment of chronic 
inflammatory disease. 
 
In this study, it was proposed to produce two forms of recombinant sCD23 for 
expression from Escherichia coli, namely: 
1) A wild type 25 kDa sCD23  and; 
2) A site-directed mutant of 25 kDa sCD23. 
 
In view of the fact that it was determined by Diamond et al. (1993) and Nham (1999) 
that the I-domain is indeed involved in β2 integrin ligand interactions and since it was 
determined by Borland et al. (2007) that the RKC motif on sCD23 is one of the 
principal interaction surfaces between sCD23 and the β5 integrin family, it was decided 
to probe the interaction surface between the I-domain of CD11 (b and c) and the RKC 
motif of sCD23. This was done by using site-directed mutagenesis and the importance 
of this motif for the CD23/CD11 interaction was verified via standard and competitive 
ELISA with peptide inhibitory analysis.  
 
Another approach that we used to determine the CD23-CD11 protein interaction was 
with flow cytometry to measure the binding of recombinant CD23 proteins (as well as 
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CD23-derived custom synthesized peptides) to monocytic cells (U937 cell line), which 
had been differentiated to increase the surface expression of β2 integrin proteins. 
 
In order to achieve these aims, the following experiments were conducted: 
 
1. Mutation of the RKC-motif of the CD23 protein via site directed mutagenesis to 
an AAC-motif. 
2. Expression of a recombinant form of the I-domain of CD11 (b and c) and 
recombinant CD23 proteins in a competent bacterial expression system. 
3. Purification of the β2 integrin I-domain of CD11 (b and c) and recombinant 
CD23 proteins. 
4. ELISA analyses between the recombinant CD11 I-domain and CD23 (a wild 
type and a mutant version). 
5. Analysis of the interaction between the I-domain of CD11 and two types of 
(custom synthesized) CD23-derived decapeptides, one containing the RKC 
motif and the other the AAC motif, also determined via ELISA. 
6. Flow cytometry analyses of the interaction between recombinant sCD23 and 
cell-surface β2 integrins, with competitive peptide inhibitory experiments. 
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3. EXPRESSION AND PURIFICATION OF CD23 AND 
THE I-DOMAIN OF CD11 
  
3.1 Introduction 
Many proteins which may be used for research or medical treatment are normally 
expressed at extremely low concentrations. However, through recombinant DNA 
technology a large quantity of proteins can be produced. This involves the insertion of 
the desired protein-encoding gene into an expression vector which must contain a 
promoter so that the protein of interest can be expressed. This vector can then be used to 
transform a host which could be a eukaryotic cell culture, yeast, viral or bacterial 
expression system. 
 
For this study, two types of vector systems were used, for CD23 we used the pET 
vector system (Novagen) and for CD11, the pGEX vector system (GE Healthcare) was 
used. 
 
3.1.1 The pET vector system 
According to Novagen, the pET vector system has been found to be the most powerful 
system yet developed for the cloning and expression of recombinant proteins in 
Escherichia coli (E. coli). This system entails cloning of the target genes into pET 
plasmids under the control of strong bacteriophage T7 transcription and translation 
signals; whereby expression is induced by providing a source of T7 ribonucleic acid 
(RNA) polymerase in the host cell. T7 RNA polymerase is so selective and active that if 
it is fully induced, nearly all of the cell‘s resources are converted to target gene 
expression. The desired protein can comprise more than half of the total cell protein 
after a few hours of induction. It is possible though, to lower the expression level by 
lowering the concentration of the inducer, which sometimes facilitates the production of 
a higher yield of soluble protein. The pET vector system is also able to maintain 
uninduced target genes in a transcriptionally inactive state. Within this vector system, 
there are two categories of vectors available, namely; transcription and translation 
vectors.  
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The transcription vectors include pET-21, pET-3 and pET-24 and express target RNA 
but do not provide translation signals. They are beneficial for proteins from target genes 
that carry their own bacterial translation signals.  These vectors are identified by the 
lack of suffix after the name.  
 
Translation vectors on the other hand contain efficient translation initiation signals and 
are designed for protein expression. Translation vectors are distinguished by the 
addition of a letter suffix following the name, eg. pET 23(a), and cloning sites are 
contained in reading frames a, b or c which corresponds to GGA,GAT or ATC triplet of 
the BamH1 site. All pET translation vectors have translation stop codons in all three 
reading frames following the cloning regions in addition to a downstream T7 
transcription terminator. Once plasmids are established in a non-expression host, they 
are frequently transformed into a host (namely, λ DE3 lysogen) bearing the T7 RNA 
polymerase gene so that the target proteins can be expressed. These hosts are lysogens 
of bacteriophage DE3, which is a lambda derivative that has the phage 21 immunity 
region as well as a DNA fragment containing the lac I gene, the lac UV5 promoter and 
the T7 RNA polymerase gene. Several different host strains are available as DE3 
lysogens but the most widely used host is E. coli BL21, which has the advantage of 
being deficient in both lon and ompT proteases. Another characteristic of pET vectors is 
that they often carry an antibiotic resistance gene in order to enable easy identification 
of positively transformed cells. Another derivative of BL21 host strains is Rosetta DE3 
which is designed to enhance the expression of eukaryotic proteins that contain codons 
which are rarely used in E. coli. Rosetta DE3 strains provide tRNA genes for AGG, 
AGA, AUA, CUA, CCC and GGA, the transcription of which is driven by their native 
promoters, on a Col-El compatible chloramphenicol resistant plasmid. In this regard, 
Rosetta strains provide for ―universal translation‖ which is normally limited by the 
codon usage of E. coli. So, once the DE3 lysogen has formed, the only promoter that is 
able to direct T7 RNA polymerase is the lac UV5 promoter, which in turn is induced by 
isopropyl-β-D-thiogalactopyranoside (IPTG). Upon the addition of IPTG, T7 
polymerase production is induced resulting in the transcription of the target DNA in the 
plasmid (Novagen, 2002). 
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A common feature of using E. coli for high expression of recombinant protein is the 
production of insoluble and inactive aggregates called inclusion bodies (IB), which are 
dense and amorphous protein deposits that can be found in bacterial cytoplasmic or 
periplasmic space. A major disadvantage is that the inclusion bodies need to be isolated, 
renatured and purified. On the other hand, there are advantages in the production of 
recombinant proteins in this way, since in most cases; the recombinant protein is 
unstable and sometimes toxic to the host cell thereby affecting the expression levels of 
the protein. Also, the expressed protein is often protected from proteases in this form. 
The relative high density of IB‘s also makes it easier for their isolation from other 
cellular proteins by centrifugation to yield highly concentrated and relatively pure 
protein (Hober and Uhlen, 1999). 
 
The main objective once the inactive and misfolded IB‘s are obtained is to convert them 
into soluble, biologically active products. The first step to achieve this is therefore to 
purify the IB from impurities by washing with a detergent. Detergents such as n-
dimethyldodecylamine N-oxide (LDAO), Triton-X-100 or low molar concentration of 
chaotrophs are normally used for this purpose. Next, the purified IB‘s need to be 
solubilised using a strong denaturant such as 6M guanidinium hydrochloride (Gdn-HCl) 
or 8M urea. However, Gdn-HCl is usually preferred to urea because it is a stronger 
chaotroph in that it is able to solubilize extremely aggregated IB‘s whereas urea may 
not solubilise the aggregates. In addition, urea solutions may also contain isocyanate 
which may lead to carbamylation of free amino groups of the polypeptide (Misawa and 
Kumagai, 1999). 
 
The addition of thiol agents such as β-mercaptoethanol or reduced glutathione (GSH) 
allows the reduction of disulphide bonds via thio-disulphide exchange which facilitates 
the solubilisation of cysteine containing compounds. After solubilisation  of the IB‘s, in 
order to obtain correctly folded proteins, excess denaturants and reducing thiol reagents 
need to be removed, which can be achieved via dialysis, chromatography, or dilution. 
Furthermore, renaturation conditions need to be optimised with regard to factors such as 
temperature, pH and ionic strength for each individual protein. Other parameters, such 
as the presence of low molecular weight compounds containing calcium (Ca 
2+
) or NaCl 
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in the renaturation buffer may also have a significant effect on the renaturation yield 
(Lilie et al., 1998). 
 
If the target protein contains disulfide bonds then the renaturation buffer has to be 
supplemented with a redox system such as reduced glutathione (GSH) or oxidized 
glutathione (GSSG) or other reduced and oxidized forms of low molecular weight thiol 
reagents in molar ratios of 5:1 to 10:1. This provides the appropriate redox potential to 
allow the formation of thiol bonds by following rapid reshuffling of incorrect disulfide 
bonds. By maintaining the pH of the renaturation buffer within the upper limit, it will 
accelerate thiol disulfide exchange, which will still allow for renaturation of the 
recombinant protein (Misawa and Kumagai, 1999). 
 
3.1.2. The pGEX-GST Gene Fusion System 
The glutathione-S-transferase (GST) Gene Fusion System is a flexible system for the 
expression, purification and detection of fusion proteins produced in E. coli. It has been 
used successfully in a variety of applications including studies involving DNA-protein 
and protein-protein studies, molecular immunology and the production of vaccines. 
This system is based on the inducible, high-level expression of genes as fusions with 
GST derived from Schistosoma japonicum (Smith and Johnson, 1988) whereby the 
fusion protein accumulates within the cell‘s cytoplasm (GST Gene Fusion System 
Handbook). 
 
The GST tag is a 211 amino acid sequence whose DNA sequence is frequently 
integrated into expression vectors for production of recombinant proteins. The result 
is a GST-tagged fusion protein in which the functional GST protein (26 kDa) is fused 
to the N-terminus of the recombinant protein. The GST-tagged fusion proteins can be 
purified or detected based on the enzyme–tag‘s ability to bind to its substrate 
glutathione. Alternatively; anti-GST antibodies are commercially available for use in 
assay methods involving GST-tagged proteins. In either case, the tag provides a 
means of specifically purifying or detecting the recombinant protein without a 
protein-specific antibody or probe. 
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GST fusion proteins are constructed by inserting a gene or gene fragment into the 
multiple cloning site (MCS) of one of the ten pGEX vectors. All pGEX vectors are 
engineered with an internal lac I
q
 gene and expression is controlled by the tac promoter, 
which is induced by the lactose analog, IPTG. The lac I
q 
gene product is a repressor 
protein which binds to the operator region of the tac promoter thereby preventing 
expression until induction by IPTG and maintaining tight control over expression of the 
insert of interest. Table 1 lists the ten pGEX vectors and the various protease cleavage 
recognition sites. Complete DNA sequences and restriction site data for the  pGEX 
vectors are available at the Amersham Biosciences web site 
(http://www.amershambiosciences.com) and from GenBank™.  
 
Table 1: The protease cleavage sites of pGEX vectors 
Vector Cleaved by 
pGEX-6P-1, pGEX-6P-2, pGEX-6P-3 PreScission Protease 
 
pGEX-4T-1, pGEX-4T-2, pGEX-4T-3 Thrombin 
pGEX-5X-1, pGEX-5X-2, pGEX-5X-3 Factor Xa 
pGEX-2TK 
Allows detection of expressed proteins by 
direct labelling in vitro   
Thrombin 
 
       
     
The pGEX P, T and X series vectors provide all three translational reading frames 
starting with an EcoRI restriction site. The same MCS in each vector ensures easy 
transfer of inserts. As for pGEX 2TK, the MCS is different from that of the other 
pGEX vectors in that this vector contains the recognition sequence for the catalytic 
subunit of cAMP-dependent protein kinase obtained from heart muscle and this 
protein kinase site is located between the thrombin recognition site and the MCS 
(Kaelin et al., 1992). 
 
It has been found that E. coli BL21 is the host of choice for GST fusion expression 
studies. Various methods for the purification of fusion proteins are available, such as 
batch preparation procedures, the use of microspin columns or pre-packed columns 
linked to chromatography systems. Batch preparations are occasionally used if it 
appears that the GST tag is not fully accessible or when the concentration of protein 
 36 
in the bacterial lysate is very low (both could appear to give a low yield from the 
affinity purification step). MicroSpin columns using centrifugation is advantageous in 
that it can be used for a single purification of a small quantity of product or for high-
throughput screening. Alternatively, for simple and reproducible purification, use of a 
chromatography system such as ÄKTAprime is advantageous since it can monitor and 
record the purification process, thus eliminating manual errors (GST Gene Fusion 
System Handbook). 
 
Yield of fusion protein is highly variable and is affected by the nature of the fusion 
protein, the host cell, and the culture conditions used. GST fusion proteins can be 
purified from bacterial lysates via affinity chromatography using immobilised 
glutathione on a matrix support (such as Sepharose or agarose) via the enzyme-
substrate binding reaction. GST fusion proteins are captured by the affinity medium 
and impurities are removed by washing with a suitable buffer. One of the most 
important parameters affecting the binding of GST fusion proteins to its matrix 
support is the flow rate. Since the binding kinetics between glutathione and GST are 
relatively slow, it is important to keep the flow rate low during sample application to 
achieve maximum binding capacity. The binding properties of the target protein can 
be improved by adjusting the sample to the composition of the binding buffer. 
Reduced glutathione (in excess) is used to elute fusion proteins under mild non-
denaturing conditions whereby protein antigenicity and function is preserved. The 
free glutathione competitively displaces the immobilized glutathione binding 
interaction with the GST, thereby allowing the fusion protein to emerge from the 
column. Cleavage of the protein from GST is optional and can be achieved by using 
site-specific proteases whose recognition sequence is situated immediately upstream 
from the MCS on the pGEX plasmid. The fusion protein can be detected using 
colourimetric or immunological methods (GST Gene Fusion System Handbook). 
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3.2 Experimental procedure 
3.2.1 Recombinant DNA analyses 
The CD11 vector construct, kindly donated by Dr. Sang-Uk Nham (Kangwon National 
University, Korea) consists of a pGEX vector (Pharmacia Biotech., U.S.A.)  containing 
the I-domain of CD11b (known as pGEXCD11bI) or CD11c (known as pGEXCD11cI). 
As illustrated in figure 8, the construct has a GST tag for affinity purification, and an 
ampicillin resistance marker. For the CD11c vector, the DNA insert encoding the 
CD11c I-domain sequence was subcloned in the BamHI and XhoI sites of a pGEX-
5T-3 vector to form the expression plasmid, pEX-CD11cI; and is predicted to be 5604 
bp in size. In the case of the CD11b vector, the DNA insert encoding the CD11b I-
domain sequence was subcloned in the BamHI and NotI sites of a pGEX-5T-3 vector 
to form the expression plasmid, pGEX-hCD11bI; and is predicted to be 5609 bp in 
size. The vector was isolated (via a Promega PureYield Plasmid Miniprep System 
plasmid isolation kit, catalogue number A1223) and consequently screened via the 
polymerase chain reaction as well as restriction enzyme digestion, followed by DNA 
sequencing to verify authenticity.  
 
 
  
 
  
   
Figure 8: Vector map of pGEX vectors containing the coding region for CD11b and CD11c I domains 
illustrating vector sizes, restriction sites and DNA inserts (pers. communication, Dr. Sang-Uk Nham). 
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The sCD23 (25 kDa) construct was previously cloned by Brodie Daniels (unpublished 
data) and was available in the NMMU laboratory. As illustrated in figure 9, the 
construct has a histidine (His) tag for affinity purification and a kanamycin resistance 
marker. The sCD23 insert [which has an open reading frame encompassing residues 
Met
150
 – Ser321, (see figure 10)] was subcloned in the XhoI and NcoI restriction sites of 
a pET -28b (+) vector  to form the expression plasmid, p28sCD23His; and is predicted 
to be 5800 bp in size. The plasmid was isolated using the Promega PureYield Plasmid 
Miniprep System, and consequently screened via PCR. 
 
                     
 
Figure 9: Vector map of pET-28b (+) containing the coding region for the soluble 25 kDa CD23. This 
region encodes from residues methione
150
 to serine 
321
.  The restriction sites used for cloning and the 
position of the tag and the DNA insert relative to the position of the various other sequence landmarks 
present on the vector are shown. 
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                               *Start codon for human sCD23 
DNA: TCGGGAGAATCCAAGCAGGACCGCCATGGAGGAAGGTCAATATTCAGAGAT 204 
A.A                            M  E  E  G  Q  Y  S  E  I   9                     
DNA: CGAGGAGCTTCCCAGGAGGCGGTGTTGCAGGCGTGGGACTCAGATCGTGCT 255 
A.A    E  E  L  P  R  R  R  C  C  R  R  G  T  Q  I  V  L  26                  
DNA: GCTGGGGCTGGTGACCGCCGCTCTGTGGGCTGGGCTGCTGACTCTGCTTCT 306 
A.A    L  G  L  V  T  A  A  L  W  A  G  L  L  T  L  L  L  43                   
DNA: CCTGTGGCACTGGGACACCACACAGAGTCTAAAACAGCTGGAAGAGAGGGC 357 
A.A    L  W  H  M  D  T  T  Q  S  L  K  Q  L  E  E  R  A  60                   
DNA: TGCCCGGAACGTCTCTCAAGTTTCCAAGAACTTGGAAAGCCACCACGGTGA 408 
A.A    A  R  N  V  S  Q  V  S  K  N  L  E  S  H  H  G  D  77                   
 
DNA: CCAGATGGCGCAGAAATCCCAGTCCACGCAGATTTCACAGGAACTGGAGGA 459 
A.A    Q  M  A  Q  K  S  Q  S  T  Q  I  S  Q  E  L  E  E  94                   
DNA: ACTTCGAGCTGAACAGCAGAGATTGAAATCTCAGGACTTGGAGCTGTCCTG 510 
A.A    L  R  A  E  Q  Q  R  L  K  S  Q  D  L  E  L  S  W 111                 
DNA: GAACCTGAACGGGCTTCAAGCAGATCTGAGCAGCTTCAAGTCCCAGGAATT 561 
A.A    N  L  N  G  L  Q  A  D  L  S  S  F  K  S  Q  E  L 128                   
DNA: GAACGAGAGGAACGAAGCTTCAGATTTGCTGGAAAGACTCCGGGAGGAGGT 612 
A.A    N  E  R  N  E  A  S  D  L  L  E  R  L  R  E  E  V 145                   
                   ↓sCD23(25kDa variant)starting at MET150 
DNA: GACAAAGCTAAGGATGGAGTTGCAGGTGTCCAGCGGCTTTGTGTGCAACAC 663 
A.A    T  K  L  R  M  E  L  Q  V  S  S  G  F  V  C  N  T 162                   
DNA: GTGCCCTGAAAAGTGGATCAATTTCCAACGGAAGTGCTACTACTTCGGCAA 714 
A.A    C  P  E  K  W  I  N  F  Q  R  K  C  Y  Y  F  G  K 179                   
DNA: GGGCACCAAGCAGTGGGTCCACGCCCGGTATGCCTGTGACGACATGGAAGG 765 
A.A    G  T  K  Q  W  V  H  A  R  Y  A  C  D  D  M  E  G 196                   
DNA: GCAGCTGGTCAGCATCCACAGCCCGGAGGAGCAGGACTTCCTGACCAAGCA 816 
A.A    Q  L  V  S  I  H  S  P  E  E  Q  D  F  L  T  K  H 213                   
DNA: TGCCAGCCACACCGGCTCCTGGATTGGCCTTCGGAACTTGGACCTGAAGGG 867 
A.A    A  S  H  T  G  S  W  I  G  L  R  N  L  D  L  K  G 230                   
DNA: GGAGTTTATCTGGGTGGATGGGAGCCACGTGGACTACAGCAACTGGGCTCC 918 
A.A    E  F  I  W  V  D  G  S  H  V  D  Y  S  N  W  A  P 247                  
DNA: AGGGGAGCCCACCAGCCGGAGCCAGGGCGAGGACTGCGTGATGATGCGGGG 969 
A.A    G  E  P  T  S  R  S  Q  G  E  D  C  V  M  M  R  G 264                   
DNA: CTCCGGTCGCTGGAACGACGCCTTCTGCGACCGTAAGCTGGGCGCCTGGGT 1020 
A.A    S  G  R  W  N  D  A  F  C  D  R  K  L  G  A  W  V 281                   
DNA: GTGCGACCGGCTGGCCACATGCACGCCGCCAGCCAGCGAAGGTTCCGCGGA 1071 
A.A    C  D  R  L  A  T  C  T  P  P  A  S  E  G  S  A  E 298                   
DNA: GTCCATGGGACCTGATTCAAGACCAGACCCTGACGGCCGCCTGCCCACCCC 1122 
A.A    S  M  G  P  D  S  R  P  D  P  D  G  R  L  P  T  P 315                  
DNA: CTCTGCCCCTCTCCACTCTTGAGCATGGATACAGCCA               1159 
       S  A  P  L  H  S  * Stop codon for humansCD23     321                                              
 
 
Figure 10: DNA and translated protein sequence for human CD23. The start (ATG) and stop (TGA) 
codons are indicated as underlined within the CD23 sequence (numbering represents the position of the 
nucleotide or amino acid in correlation with the human CD23 gene or protein). Amino acid (A.A) 
residues are shown in red with the corresponding DNA sequence shown in black. [Obtained from 
Genbank, accession code NM002_002 and NP001_993] 
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3.2.1.1 Plasmid isolation 
For the isolation of the pGEX vector, an overnight culture of E. coli BL21 (DE3) 
containing the desired plasmid was prepared by inoculating 5 mL of Luria-Bertani 
(LB) broth (10 g Tryptone, 10 g NaCl, 5 g Yeast extract, 1 mL 1 M NaOH in 1 L 
ddH2O), containing ampicillin at 100 μg/mL, with a single colony. 
 
In the case of the pET vector, an overnight culture of Rosetta (DE3) containing the 
desired plasmid was prepared by inoculating 5 mL LB broth containing kanamycin at 
15 μg/mL and chloramphenicol at 36 μg/mL, with a single colony.  
 
Cultures were incubated at 37 ºC with constant agitation for ± 16 hours and the 
relevant plasmids were isolated according to manufacturer instructions. 
 
3.2.1.2 The Polymerase chain reaction 
For amplification of the CD11 insert, the pGEX-CD11 I-domain vector construct was 
used as template DNA for PCR. The PCR reaction was conducted with 1 μL of 
template DNA, 10 μL of KAPPA Taq PCR Ready-mix (Kapa Biosystems, catalogue 
number KK1008) and 1 μL each of the pGEX forward 
(5‘GGGCTGGCAAGCCACGTTTGGTG-3‘) and reverse primer 
(5‘CCGGGAGCTGCATGTGTCAGAGG-3‘) at 100 pmols/μL. The reaction volume 
was made up to 25 μL with nuclease free H2O. A negative control, containing the 
same mixture as above but excluding the template DNA was included.  
 
As for amplification of the wild type sCD23 insert, the pET - 28b (+) vector was used 
as template and T7 forward primer (5‘TAATACGACTCACTATAGGG-3‘) and T7 
TERM reverse primer (5‘GCTAGTTATTGCTCAGCGG-3‘) were used. For the 
mutant sCD23, the resultant mutated vector (from SDM) served as template and T7 
forward and T7 TERM primers were used to amplify the mutated insert.  
 
The PCR conditions were one cycle of denaturation at 95 ºC for 2 minutes, followed 
with 25 cycles of denaturing, annealing and elongation. The denaturing was 
conducted at 95 ºC for 45 seconds, annealing at 55 ºC for 1 minute and elongation at 
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72 ºC for 3 minutes. These 25 cycles were then followed by another elongation cycle 
at 72 ºC for 15 minutes. The PCR reaction was conducted using a Rapid Cycler from 
Idaho Technologies. 
 
3.2.1.3 Agarose gel electrophoresis 
Agarose gel electrophoresis was performed in order to confirm plasmid isolation, 
PCR amplification and restriction enzyme digestion. The procedure entailed using a 
1% agarose gel in Tris-acetate-EDTA buffer (TAE) (242 g Tris base, 57.1 mL glacial 
acetic acid, 100 mL 0.5 M EDTA at pH 8) according to the method described by 
Sambrook et al. (1989). After loading samples as well as a sized marker (Fermentas, 
Generuler
TM
 1kb DNA ladder) in their respective wells, the gel was run at 90 V, 400 
mA for 45 minutes or until the tracking dye (containing xylene cyanol and 
bromothymol blue) reached three quarters of the way down the gel. The gel was 
removed and viewed on a transilluminator and digital photographs were taken using 
an AlphaImager
TM
 3400. 
 
3.2.1.4 UV spectrophotometry determination of DNA concentration and purity  
The purity of the DNA sample was determined using the OD260nm:OD280nm ratio, 
where a ratio of 2.00 indicates 100% nucleic acids and no protein and ratios less than 
2.00 indicate an increasing amount of protein. Since an OD260nm of 1 represents 30 
μg/mL single-stranded or 50 μg/mL double-stranded DNA or RNA, the DNA 
concentration was determined by using the following equations (Sambrook et al., 
1989): 
 
[DNA/RNA] (μg/mL) = OD260nm x 30 x dilution factor (for single stranded DNA) 
 
or 
 
[DNA] (μg/mL) = OD260nm x 50 x dilution factor (for double stranded DNA) 
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3.2.1.5 Restriction digestion 
The CD11 I-domain insert was verified via restriction digestion and was carried out 
using between 2 and 5 μL of plasmid DNA depending on the concentration of the 
DNA. The restriction digestion was carried out according to Sambrook et al. (1989) 
and Nham (1999). Agarose gel electrophoresis (section 3.2.1.3) of the digested 
fragments was used to verify whether successful digestion had occurred. 
  
Once we were able to verify that the CD11 insert was authentic it was decided to 
transform the vector I-domain construct as well as a mutant version of the CD23 
construct (see section 3.2.1.7) into E. coli Rosetta (DE3) cells in order to optimize 
expression of the protein of interest.  As for the wild type CD23 construct, there was 
no need to transform the construct since the host strain in which the vector originally 
had been cultured (from glycerol stocks prepared by B. Daniels, NMMU, Port 
Elizabeth, South Africa) was already contained within the Rosetta (DE3) strain. 
 
3.2.1.6 The preparation of chemically competent cells  
Competent cells are required for transformations whereby plasmids are inserted into 
bacterial cells to allow cloning or expression of the plasmid. Since DNA is a very 
hydrophilic molecule, it won't normally pass through a bacterial cell's membrane. In 
order to make bacteria take in the plasmid, they must first be made "competent" to take 
up DNA. This is done by creating small holes in the bacterial cells by suspending them 
in a solution with a high concentration of calcium. 
 
Chemically competent cells were prepared by culturing E. coli  Rosetta (DE3) in 5 
mL 2xYT broth (16 g tryptone, 10 g yeast extract and 5 g NaCl dissolved in 1L 
distilled water and adjusted to pH 7.5 before autoclaving) containing 36 µg/mL 
chloramphenicol at 37 ºC for  ± 16 hours. A 1:200 inoculation was made of the 
culture into prewarmed YT broth containing 36 µg/mL chloramphenicol followed by 
incubation at 37 ºC with constant agitation until an O.D.600nm of  between 0.3 and 0.4 
was reached. These cells were incubated on ice for 10 minutes followed by 
centrifugation at 2500 x g for 10 minutes. The supernatant was discarded and the cells 
resuspended in 2 x 7 mL of CM solution (50 mM CaCl2, 1 mM EDTA, pH8 and 
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dissolved in 100 mL deionised distilled water) and incubated further on ice for 30 
minutes. The cells were once again centrifuged at 2500 x g for 10 minutes and the 
supernatant discarded. The pellet was resuspended in 3.7 mL CM solution, followed 
by incubation on ice for 30 minutes. DMSO (125 µL) was added and the cells were 
incubated on ice for 30 minutes followed by another addition of 125 µL DMSO while 
cells were kept on ice for 30 minutes once again, followed by transferring 100 μL 
aliquots of competent cells to microcentrifuge tubes and snap frozen in liquid nitrogen. 
Competent cells were stored at -80 ºC until further use. 
 
3.2.1.7 Transformation of chemically competent cells  
The purpose of this technique is to introduce a foreign plasmid into a bacterial cell in 
order to amplify the plasmid so that large quantities of this plasmid can be produced. 
This is based on the natural function of a plasmid: to transfer genetic information vital 
to the survival of the bacteria. Once cells are made competent, DNA can be forced into 
cells by incubating the cells and DNA together on ice, placing them briefly at 42 
o
C 
(heat shock), and putting them back on ice. This causes the bacteria to take in the DNA.  
 
The procedure entailed thawing 40 µL of chemically competent cells on ice and adding 
2 µL of plasmid DNA. The cells were mixed gently by swirling, followed by further 
incubation on ice for 15 minutes. This was followed by incubation at 42 
o
C for 30 
seconds exactly and the cells were placed back on ice for 2 minutes before adding 100 
µl of LB broth and incubation at 37 ºC for 1 hour. The cells were spread onto LB 
plates containing the appropriate antibiotic. Thus for cells transformed with the 
CD11b/c construct, ampicillin at 100 μg/mL and chloramphenicol at 36 μg/mL 
supplemented the LB agar and for cells transformed with the mutant sCD23 construct, 
chloramphenicol (36 μg/mL) and kanamycin (15 μg/mL) was used (Sambrook et al., 
1989). 
 
The vector of interest was once again isolated and screened via PCR or restriction 
enzyme digestion and finally sequenced. 
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3.2.1.8 Site-Directed Mutagenesis (SDM) of recombinant sCD23 
Based on our hypothesis that the sCD23 interaction surface involved a particular RKC-
motif located in the lectin head domain region of the sCD23 protein, it was decided to 
create a mutant version of this RKC-motif so that we would be able to distinguish if 
there were any differences in binding involving the wild type RKC-motif or the mutant 
version (in this case AAC) of this motif. We thus made use of site-directed 
mutagenesis. 
The basic procedure requires the synthesis of a short DNA primer which is 
complementary to the template DNA around the site where the mutation is to be 
introduced. The mutation may be a single base change, deletion or insertion. This 
synthetic primer is complementary to the template DNA around the base change so it 
can hybridize with the DNA containing the gene of interest. The single-stranded 
primer is then extended using a DNA polymerase, which copies the rest of the gene. 
The gene thus copied contains the mutated site, and is then introduced into a host cell 
as a vector and cloned. Finally, mutants are selected. 
Site-directed mutagenesis was executed by using the QuickChange Lightning Site-
Directed Mutagenesis Kit, (Stratagene, catalogue number 210518), according to 
manufacturer instructions. According to Stratagene, this kit delivers mutant plasmids 
without losses in mutagenesis efficiency or accuracy and has been optimized for 
mutagenesis of plasmids of up to 14 kb. It allows for rapid, efficient and accurate 
mutagenesis of small and large plasmids with a single kit.  
 
Mutant strands were synthesized by denaturing the sCD23 (25 kDa) expression plasmid 
(shown in figure 9) and annealing mutagenic primers containing the desired mutation. 
In this case our focus was on the RKC motif of the 25 kDa sCD23. With reference to 
figure 10, the peptide region containing the amino acid sequence INFQRKCYYFG 
(residues 168 to 178) was mutated to INFQAACYYFG. The mutagenic primers 
(spanning the target region and containing the changed nucleotides to encode alanine in 
the RKC motif) that were designed for this experiment were:  
 45 
5‘ATCAATTTCCAAGCGGCGTGCTACTACTTCGG-3‘ (forward) and 
5‘CCGAAGTAGTAGCACGCCGCTTGGAAATTGAT-3‘ (reverse). 
 
The synthesis reaction contained 5 μL of 10x Quickchange reaction buffer, 2 μL of 
template sCD23 (25 kDa), 2 μL each of forward and reverse  primer, 1 μL of 
Quickchange dNTP mix, 1.5 μL of Quickchange reagent and 1 μL of Quickchange 
enzyme followed by sterile distilled water to a final volume of 50 μL. A control 
reaction containing the same mixture as above was used except Quickchange control 
primers replaced the primers designed for the mutant and a pWhitescript control 
template replaced the wild type sCD23 template. This reaction was conducted using a 
Rapid Cycler from Idaho Technologies. 
 
The following cycling parameters were used: 
 1) 1 cycle of denaturation at 95 ºC for 2 minutes, followed with  
 2) 18 cycles of denaturing, annealing and elongation. The denaturing was conducted 
at 95 ºC for 20 seconds, annealing at 60 ºC for 10 seconds and elongation at 68 ºC for 
30 seconds/kb of plasmid length.  
3) These 18 cycles were followed by another elongation cycle at 68 ºC for 5 minutes.  
 
Once the mutant primers were extended and incorporated with a Pfu-based DNA 
polymerase blend, the amplified cDNA was treated with DpnI to remove unwanted or 
parental plasmid, followed by transforming the mutated molecules into E. coli Rosetta 
(DE3) according to the mutagenesis kit instructions. DNA sequencing (section 3.2.1.9) 
was used to confirm the presence of the mutants. 
 
3.2.1.9 DNA sequencing  
Isolated plasmids containing the CD11b/c I-domain gene sequence and those 
containing the mutated sCD23 gene sequence were sent to the DNA sequencing 
facility of the Stellenbosch University for sequencing by an automated DNA 
sequencer using the dye terminator sequencing method of Sanger (1981). 
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3.2.2 Recombinant protein expression 
3.2.2.1 Test expression of recombinant proteins 
Test expressions of the relevant proteins of interest were carried out by inoculating 5 
mL LB broth (with appropriate antibiotic) with a single colony followed by overnight 
incubation at 37 ºC with constant shaking at 180 rpm on an orbital shaker. A 250 μL 
aliquot of the overnight culture was used to inoculate 50 mL prewarmed LB broth, 
containing the appropriate antibiotic, followed by incubation at 37 ºC with rotation at 
180 rpm. The absorbance at 600 nm was monitored and once the O.D600nm reached 0.5 
- 0.7, the cells were harvested by removing 900 μL to a sterile Eppendorf tube and 
adding 100 μL of 80% glycerol (filter sterilized). This glycerol stock was stored at -80 
ºC.  
 
Concurrently, another 500 μL of culture was removed and aliquoted into a sterile 
Eppendorf tube and the cells were pelleted by centrifugation and the supernatant 
discarded. This dried pellet represented the pre-induction sample and was stored at -
20 ºC and later electrophoresed on a 15% SDS-PAGE gel under reducing conditions. 
After removal of the 500 μL of culture, protein expression was induced in the 
remaining 50 mL of culture by adding IPTG to a final concentration of 1 mM from a 
1 M filter sterilized stock. Growth was further monitored by taking absorbance 
readings at 600 nm at 1, 2, 3 and 24 hours after induction. At each of these time 
intervals, another 500 μL of sample was removed and the cells pelleted as before, for 
later use in electrophoresis. 
 
Once all the samples were obtained, the cell pellets were loosened and 100 times the 
OD600 nm of double-strength Laemmli (1970) SDS-PAGE reducing sample buffer was 
added to lyse cells. These cells were heated at 95 ºC for 1 hour to completely lyse 
cells before executing SDS-PAGE. 
 
3.2.2.2 Preparative expression of recombinant proteins 
Preparative expression of protein was performed exactly as for test expression, except 
that 3 x 1 L cultures were induced with 1 mM IPTG for the optimal time established 
by the test expressions, which was 3 hours for both the wild type and mutant CD23. 
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Cells were harvested by centrifugation at 5500 x g for 20 minutes at 4 ºC in a 
Beckman Avanti-J25 centrifuge.  
 
The cell pellet from 1 L of culture of sCD23 was resuspended in 10 mL of 
sonification buffer (50 mM Tris –HCl, pH 7.8, 0.3 M NaCl and 0.2% NaN3) and 
stored at -80 ºC in 50 mL Falcon tubes. 
 
Similarly, the cell pellet from 1 L culture of CD11 b/c I-domain was resuspended in 
10 mL I-domain isolation buffer (20 mM Tris-HCl, and 10 mM EDTA, pH 7.5) and 
stored at -80 ºC in 50 mL Falcon tubes. 
 
3.2.3 Purification of recombinant CD11 I-domain  
3.2.3.1 Affinity chromatography 
The cells harvested from expressions were thawed, combined and ruptured by 
sonication using a Bandelin Sonopuls HD2200. Keeping the samples on ice, samples 
were sonicated  for six bursts of three minutes, pulsing at 50% duty cycle and 40% 
power followed by centrifugation at 4 ºC for 30 minutes at 4000 x g in an Eppendorf 
5804R centrifuge fitted with an A-4-44 rotor. The supernatant was retained and 
further concentrated to between 5-10 mL using Amicon Ultracentrifugal filters.  This 
concentrated protein solution was filtered using a 0.45 μm syringe filter and loaded 
onto  two 1 mL GSTrap FF columns linked in series (for easy scale-up purposes) in 
combination with an ÄKTA FPLC (Amersham Pharmacia Biotech). Binding buffer 
(20 mM Tris-HCl, pH 8.0) was used to equilibrate the column and the fusion protein 
was eluted by 10 mM reduced glutathione in 20 mM Tris-HCl, pH 8.0. The purified 
fusion protein was dialyzed against phosphate-buffered saline (PBS, pH 7.4) after 
assessment of homogeneity of the eluted protein by SDS–PAGE. 
 
3.2.3.2 Spin column purification 
We also made use of a GST Spin Purification Kit [Pierce, (USA) catalogue no 16106]. 
The procedure entails application of the GST-tagged CD11 I-domain cell lysate to 
prepacked spin columns; where the column support consists of glutathione that has been 
immobilized by its central sulfhydryl group via a 12-atom spacer arm to crosslinked 6 
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% beaded agarose.  The applied GST-tagged protein binds specifically to the affinity 
medium whereby impurities are removed by washing with a suitable buffer (e.g., Tris 
buffer). Bound protein is easily dissociated (eluted) by competitive displacement with 
buffer containing free, reduced GSH. The technique thus provides a mild purification 
process that does not affect a protein‘s native structure and function. Sample 
application, washing, and elution were performed according to manufacturer‘s 
instructions. 
 
3.2.3.3 Western blot 
Western blotting is a technique used for the analysis of individual proteins in a protein 
mixture, such as a cell lysate, for example. Initially the protein mixture is applied to gel 
electrophoresis in a carrier matrix (such as SDS-PAGE, isoelectric focusing, 2D-PAGE 
etc.) in order to separate the proteins according to size, charge or other differences in 
individual protein bands. The next step involves transferring the separated protein bands 
to a carrier membrane such as nylon, nitrocellulose or polyvinylidene difluoride 
(PVDF). This process is called blotting. Due to hydrophobic and / or ionic interactions 
the proteins adhere to the membrane in the same pattern as they have been separated. 
Next, the membrane is blocked to prevent any non-specific binding of antibodies to the 
surface of the membrane. Most commonly the transferred protein is complexed with an 
enzyme-labeled antibody as probe. Once an appropriate substrate is added to the 
antibody conjugate, a detectable product (such as a chromogenic precipitate) is 
produced on the membrane for colourimetric dectection. Alternatively, fluorescently 
tagged antibodies can be used which are directly detected with the aid of a fluorescence 
imaging system (Burnette, 1981). 
 
Proteins that were separated using SDS-PAGE (performed in 10% acrylamide gels) 
were transferred to an Immobilon PVDF membrane for Western Blotting. After 
electrophoresis, the SDS-PAGE gel was placed in transfer buffer (48 mM Tris, 39 
mM glycine, 20% (w/v) methanol) for 20 minutes to allow for the equilibration of the 
gel. A piece of Immobilon PVDF membrane, the size of the gel was pre-wet in 5-10 
mL 100% methanol for 5 seconds followed immediately with soaking in 500 mL 
dH2O for 10 minutes to remove the methanol. The membrane was equilibrated for 20 
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minutes in 500 mL transfer buffer. Six pieces of blotting paper were also equilibrated 
in transfer buffer. 
 
The blotting cassette was assembled as explained in the Bio-Rad instruction manual 
for the Transblot® SD semi-dry electrophoretic cell. The sandwich was stacked in the 
order of 3 pieces of thick blot paper, membrane, gel and three pieces of thick blot 
paper. Air was removed from between the layers after each layer was stacked. The 
cathode was connected on top of the sandwich followed by the safety cover. The 
transfer was carried out at 25 V with a constant current of 5 mA/cm
2
 for 2 hours. 
 
Once transfer was complete the membrane was placed directly into blocking solution 
[3% (w/v) Bovine serum albumin (BSA)  in 1 x PBS (140 mM NaCl, 2.7 mM KCl, 10 
mM Na2HPO4, 1.8 mM KH2PO4 pH 7.3, containing 0.02% (w/v) sodium azide] and 
incubated with agitation at room temperature for 30 minutes and then transferred to 4 
ºC overnight. 
 
A 1:10000 dilution of anti-GST rabbit polyclonal antibody (Calbiochem, catalogue 
number PC53) in PBS was prepared and the membrane was further incubated in this 
antibody–buffer mixture overnight at 4 ºC. The antibody-buffer mixture was 
discarded and the membrane briefly rinsed (thrice) with 100 mL of wash buffer [1x 
PBS-Tween (0.05%) (PBS-T)] to remove most of the unbound antibody. After 
decanting and discarding the rinse buffer, the membrane was once again washed with 
100 mL of wash buffer for 10 min at ambient temperature with gentle shaking after 
which this buffer was discarded.  A 1:20000 dilution of secondary antibody (anti-
rabbit IgG conjugated to horseradish peroxidase (Calbiochem, catalogue number 
DC03L) was prepared in PBS and the membrane was consequently incubated for 1 
hour in this secondary antibody mixture with gentle shaking. The membrane was 
washed as before and the blot was developed with TMB substrate (Sigma, catalogue 
number, T0565) (GST Gene Fusion System Handbook). Digital photographs were 
taken using an AlphaImagerTM 3400. 
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3.2.4 Purification of wild type human and mutant sCD23 
3.2.4.1 Inclusion body isolation 
The cells harvested from expressions were thawed and lysozyme (Roche) was added 
to a concentration of 1 mg/mL followed by incubation at room temperature for 1 hour, 
mixing end-over-end. The cells were chilled and transferred to a prechilled Rosette 
vial, kept on ice, followed by sonication for six bursts of three minutes, pulsing at 
50% duty cycle and 40% power with a Bandelin Sonopuls HD2200. The cells were 
centrifuged at 25750 x g for 30 minutes at 4 ºC using a Beckman JA 25.50 rotor. The 
pellet was resuspended in approximately 15 mL of inclusion body wash buffer (50 
mM Tris-HCl, pH 7.8, 0.3 M NaCl, 0.2% NaN3 and 0.5% lauryldimethylamine oxide 
or LDAO). A Potter-Elvehjham homogeniser was used to resuspend the inclusion 
bodies, with 5 – 6 strokes on ice. The washes were pooled and centrifuged as before, 
keeping an aliquot of the wash supernatant for SDS-PAGE analysis. The inclusion 
bodies were continuously washed until all the E. coli proteins were removed (more or 
less 8 washes). The washed inclusion bodies were consequently resuspended in 2-3 
mL of sonication buffer and stored at 4 ºC. 
 
3.2.4.2 Refolding of protein using the rapid dilution technique 
The refolding procedure was performed as described by Daniels et al. (2005). A 
protein stock was prepared from the inclusion body preparation by diluting 1 part 
inclusion bodies to 10 parts 6 M guanidinium hydrochloride in 20 mM Tris-HCl, pH 
8.0, containing 0.02% NaN3. β-mercaptoethanol was added to a final concentration of 
100 mM. The protein concentration was determined by measuring the absorbance at 
280 nm, where a 280 nm reading of 1 ~ 0.8 mg/mL. Therefore the following equation 
was used: 
 
[Protein] (mg/mL) = OD280nm x 0.8 x dilution factor 
 
The protein stock solution was added dropwise and very slowly to 500 mL refolding 
buffer (1.5 M arginine, 100 mM Tris, 150 mM NaCl and 10 mM CaCl2, pH 8 
containing GSH (reduced glutathione) to a final concentration of 5 mM and GSSG 
(oxidised glutathione) to a final concentration of 0.5 mM) at 4ºC with constant 
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stirring. The redox potential of the solution was monitored until it was below 1 mM 
free thiols. The refolding buffer was removed by overnight dialysis at 4°C against 
TNC buffer (100 mM Tris, 150 mM NaCl and 10 mM CaCl2, pH8). The protein 
solution was concentrated using an Amicon stirred ultrafiltration cell (Millipore) 
under nitrogen pressure. 
 
3.2.4.3 Measurement of the redox potential  
This method is based on the reaction of the thiol with 5, 5‘-dithiobis (2-nitrobenzoic 
acid) (DTNB) to give the mixed disulphide and 2-nitro-5-thiobenzoic acid (TNB) that 
can then be quantified by absorbance at 412 nm (Aitken and Learmonth, 1996). 
 
The redox potential of the refolding buffer was monitored using Ellman‘s reagent. 
This method entailed pipetting 25 μL of 1 M Tris (pH 8), 2 μL 100 mM DTNB 
(prepared in ethanol) and 4 μL of the refolding buffer into a 1 mL disposable cuvette 
and the final sample volume was made up to 500 μL with ddH2O. The absorbance 
was measured at 412 nm using an Ultrospec 2000 spectrophotometer (Pharmacia 
Biotech). The absorbance obtained is then used to calculate the redox potential, using 
a molar extinction coefficient of 13 600 cm
-1
M
-1
 (Ellman, 1959). Subsequently, the 
redox potential (mM) was calculated by the following equation: 
 
Redox potential (mM) = (OD412/13 600 M
-1
cm
-1
) x 1000 x dilution factor 
 
3.2.4.4 Gel-Filtration Chromatography  
After refolding, the concentrated protein solution was passed through a Superdex 75 
(26/60) gel filtration chromatography column using an ÄKTA FPLC (Amersham 
Pharmacia Biotech). This was carried out by injecting a 2 mL sample of the protein 
with a flow rate of 1 mL per minute with TNC buffer pH 8 as eluent. The fractions 
collected were 5 mL in volume and the relevant peaks were pooled together and 
concentrated using Amicon Ultracentrifugal filters. The protein concentration was 
determined using the bicinchoninic acid assay (Smith et al., 1985) and the 
homogeneity of the purified protein was assessed via SDS-PAGE. 
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3.2.4.5 SDS-PAGE gel electrophoresis 
SDS-PAGE was performed in 15% acrylamide gels according to the method 
described by Laemmli (1970). 
 
3.2.4.6 Bicinchoninic acid protein assay  
According to Hay and Westwood (2002) and Smith et al. (1985), the bicinchoninic 
acid (BCA) assay is a colourimetric method for measurement of total protein in 
aqueous solution and is based on the reduction of Cu
2+
 to Cu
+ 
by protein in an alkaline 
medium and the detection of the resulting cuprous cation by bicinchoninic acid. The 
main limitation with this assay is that for GST-fusion proteins, the sample must first 
be dialyzed against 2000 volumes of 1x PBS to remove glutathione, which can 
interfere with protein measurement (GST Gene Fusion System Handbook). 
Consequently, all samples were first dialyzed against PBS before further analyses. 
 
The working reagent was prepared by mixing 50 parts of reagent A (1 g sodium 
bicinchoninate, 2 g Na2CO3, 0.16 g sodium tartrate, 0.4 g NaOH, 0.95 g NaHCO3 in 
100 mL ddH2O at pH 11.25) with 1 part of reagent B (0.4 g CuSO4•5H2O in 10 mL 
H2O). After pipetting 10 μL of the protein sample into a well in a microtitre plate, 200 
μL of the working reagent was added to each well. The samples were mixed by 
shaking on a Multiscan MS microtitre plate reader, covered and incubated at 37 ºC for 
60 minutes. The absorbance was measured at 540 nm using a Multiscan MS microtitre 
plate reader (Labsystems) and the assay calibrated with BSA.  
 
 
 
 
 
 
 
 
 
 
 53 
3.3. Results and Discussion 
3.3.1 Analysis of the native sCD23 and its mutant 
3.3.1.1 Molecular analyses of the native and mutant sCD23: 
The wild type sCD23 (25 kDa) expression vector, which was previously cloned by 
Daniels (unpublished data), was isolated and used as template to amplify the vector 
insert as illustrated in Figure 11A.  Due to the position of the CD23 encoding region 
between the XhoI and NcoI restriction sites (figure 9), we expect to see an insert of 
approximately 600 base pairs (bp). The molecular size marker in lanes 4 and 8 (with 
base pair sizes shown as numbering on the right hand side of the figure) identifies 
amplification in lanes 1 and 2, of a fragment in the region of just below 750 bp, 
suggestive of a positive result for the amplification of the native sCD23 fragment. 
Lane 7 represents a negative control and lanes 3, 5 and 6 represent the isolated uncut 
pET -28b (+) plasmid. The multiple bands that we see in the uncut plasmid sample are 
due to differential migration of relaxed, coiled and supercoiled circular DNAs (Levy, 
2000).  
 
Figure 11B illustrates the amplified mutant CD23 insert in lanes 2 and 3 respectively, 
along with the molecular size marker in lane 1 (with DNA base pair sizes illustrated 
on the left) and the isolated mutated CD23 plasmid shown in lane 4. The size of the 
mutant CD23 amplicon (which is expected to be the same size as the wild type CD23 
insert) correlates to a fragment of roughly below 750 bp, which is suggestive of a 
positive result for the amplification of the mutant sCD23 (25 kDa) fragment.  
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  1        2          3        4           5     6    7    8    
 
 
 
B)    
                        1       2       3        4 
                   
 
 
 
Figure 11: DNA analyses of sCD23-encoding plasmids: A) wild type human sCD23 construct and 
PCR-amplified insert via agarose (1%) gel electrophoresis - 1) 2 μL vector insert amplicon; 2) 4 μL vector 
insert amplicon; 3) 1 μL isolated plasmid; 4) DNA base ladder 5) 2 μL isolated plasmid;  6) 4 μL isolated 
plasmid,  7) negative control; 8) DNA base ladder, B) mutant sCD23 via 1% agarose gel electrophoresis:  
1) DNA base pair ladder; 2) 2 μL amplified insert; 3) 4 μL amplified insert; 4) isolated mutant plasmid 
 
After transformation of the mutated CD23 plasmid into Rosetta (DE3) E. coli cells, an 
overnight culture of the cells was grown to facilitate isolation of the plasmid and was 
consequently sent for DNA sequencing at the University of Stellenbosch (Figure 12). 
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The sequence of the mutant form of sCD23 was edited to begin from its start codon 
(ATG) and was consequently aligned with the human sequence of CD23 (obtained 
from Genbank, accession number - BC064417). The Nucleotide Blast alignment tool 
software on the NCBI website, available at http://www.Blast.ncbi.nih.gov/Blast was 
used to align the base pairs. The alignment gave a clear and positive result.  
 
DNA sequences were translated using the Translate Blast (tblastn) tool, also available 
on the NCBI website and aligned with the human sCD23 protein sequence (obtained 
from UniprotKB, accession code P06734) as shown in Figure 13. The protein 
sequences aligned indicated that mutation had indeed occurred at amino acid residues 
Arg
172
 and Lys
173
 (RKC motif) of sCD23 where arginine and lysine in the RKC-motif 
had been mutated to alanine such that the motif read Ala
172
Ala
173
Cys
174 
(AAC). 
 
 56 
 
HCD23  943   ATGGAGTTGCAGGTGTCCAGCGGCTTTGTGTGCAACACGTGCCCTGAAAAGTGGATCAAT  1002 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MCD23    1   ATGGAGTTGCAGGTGTCCAGCGGCTTTGTGTGCAACACGTGCCCTGAAAAGTGGATCAAT    60 
 
HCD23  1003  TTCCAA-CGGAAGTGCTACTACTTCGGCAAGGGCACCAAGCAGTGGGTCCACGCCCGGTA  1061 
             |||||| |||  |||||||||||||||||||||||||||||||||||||||||||||||| 
MCD23   61   TTCCAAGCGG-CGTGCTACTACTTCGGCAAGGGCACCAAGCAGTGGGTCCACGCCCGGTA   120 
 
HCD23  1062  TGCCTGTGACGACATGGAAGGGCAGCTGGTCAGCATCCACAGCCCGGAGGAGCAGGACTT  1121 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MCD23  121   TGCCTGTGACGACATGGAAGGGCAGCTGGTCAGCATCCACAGCCCGGAGGAGCAGGACTT   180 
 
HCD23  1122  CCTGACCAAGCATGCCAGCCACACCGGCTCCTGGATTGGCCTTCGGAACTTGGACCTGAA  1181 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MCD23  181   CCTGACCAAGCATGCCAGCCACACCGGCTCCTGGATTGGCCTTCGGAACTTGGACCTGAA   240 
 
HCD23  1182  GGGGGAGTTTATCTGGGTGGATGGGAGCCACGTGGACTACAGCAACTGGGCTCCAGGGGA  1241 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MCD23  241   GGGGGAGTTTATCTGGGTGGATGGGAGCCACGTGGACTACAGCAACTGGGCTCCAGGGGA   300 
 
HCD23  1242  GCCCACCAGCCGGAGCCAGGGCGAGGACTGCGTGATGATGCGGGGCTCCGGTCGCTGGAA  1301 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MCD23  301   GCCCACCAGCCGGAGCCAGGGCGAGGACTGCGTGATGATGCGGGGCTCCGGTCGCTGGAA   360 
 
HCD23  1302  CGACGCCTTCTGCGACCGTAAGCTGGGCGCCTGGGTGTGCGACCGGCTGGCCACATGCAC  1361 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MCD23  361   CGACGCCTTCTGCGACCGTAAGCTGGGCGCCTGGGTGTGCGACCGGCTGGCCACATGCAC   420 
 
HCD23  1362  GCCGCCAGCCAGCGAAGGTTCCGCGGAGTCCATGGGACCTGATTCAAGACCAGACCCTGA  1421 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MCD23  421   GCCGCCAGCCAGCGAAGGTTCCGCGGAGTCCATGGGACCTGATTCAAGACCAGACCCTGA   480 
 
HCD23  1422  CGGCCGCCTGCCCACCCCCTCTGCCCCTCTCCCACTC  1458 
             ||||||||||||||||||||||||||||||||||||| 
MCD23  481   CGGCCGCCTGCCCACCCCCTCTGCCCCTCTCCCACTC   517 
 
 
                                
Figure 12: DNA sequencing results for mutant sCD23 in p28sCD23His pET vector aligned with the 
human CD23 sequence (accession number BC064417). HCD23 indicates the published human CD23 
sequence and MCD23 indicates the mutated sequence. The numbers on the left and right show the 
position in the sequence, and the vertical lines indicate proper alignment. The mutated bases are 
highlighted. 
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HCD23  150  MELQVSSGFVCNTCPEKWINFQRKCYYFGKGTKQWVHARYACDDMEGQLVSIHSPEEQDF  209 
            MELQVSSGFVCNTCPEKWINFQ  CYYFGKGTKQWVHARYACDDMEGQLVSIHSPEEQDF 
MCD23    1  MELQVSSGFVCNTCPEKWINFQAACYYFGKGTKQWVHARYACDDMEGQLVSIHSPEEQDF   60 
 
HCD23  210  LTKHASHTGSWIGLRNLDLKGEFIWVDGSHVDYSNWAPGEPTSRSQGEDCVMMRGSGRWN  269 
            LTKHASHTGSWIGLRNLDLKGEFIWVDGSHVDYSNWAPGEPTSRSQGEDCVMMRGSGRWN 
MCD23   61  LTKHASHTGSWIGLRNLDLKGEFIWVDGSHVDYSNWAPGEPTSRSQGEDCVMMRGSGRWN  120 
 
HCD23  270  DAFCDRKLGAWVCDRLATCTPPASEGSAESMGPDSRPDPDGRLPTPSAPLHS  321 
            DAFCDRKLGAWVCDRLATCTPPASEGSAESMGPDSRPDPDGRLPTPSAPLHS 
MCD23  121  DAFCDRKLGAWVCDRLATCTPPASEGSAESMGPDSRPDPDGRLPTPSAPLHS  169 
 
 
 
Figure 13: Translation of mutant sCD23 (MCD23 in figure) and alignment with human sCD23 
protein sequence (HCD23 in figure). The mutant sCD23 sequence begins at Met 
150 
and ends at Ser
321 
of human sCD23. The mutated amino acid sequence is shown in red. 
 
 
3.3.1.2 Expression and purification of sCD23 
After isolation of the plasmid, an overnight culture of the cells was grown in E. coli 
Rosetta (DE3) cultures containing 1% glucose to facilitate expression of the native 
sCD23 and mutant sCD23. Test expression (results not shown) showed that protein 
expression is strongly up-regulated after three hours post induction with IPTG for both 
the wild type and mutant protein. Hence, the preparative expression was carried out 
accordingly as shown in figure 14.  An intense protein band that is located just below 
the 26 kDa molecular weight marker indicates successful expression of the 
recombinant sCD23 after induction. The expected size for the wild type CD23 protein 
is 25 kDa, thus corresponding well with the banding pattern shown on the gel. 
 
 
 
 
 
 
                                   
 58 
 
A)                      1                 2                          3                     4                 5 
                   
 
B)                         1                2                  3               4                   5                 6    
                  
 
 
Figure 14: Analysis of CD23 preparative expression: A - Wild type human sCD23 preparative 
expression: 1) peqGOLD protein marker IV; 2) 0 hours induction; 3) 3 hours post IPTG induction; 4) 2 
hours post IPTG induction; 5) 1 hour post IPTG induction. B) Mutant CD23 preparative expression: 1) 
peqGOLD protein marker IV; 2) 0 hrs induction; 3) 1 hr post IPTG induction; 4) 2 hrs post IPTG 
induction and 5) 3 hrs post IPTG induction; 6) peqGOLD protein marker IV. 
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Once the cells were harvested, lysed and sonicated, the inclusion bodies were isolated 
by repeated washing with inclusion body wash buffer.  The supernatants of each wash 
as well as the pellet from the final wash (which consequently was resuspended in 2 mL 
sonification buffer) was retained and analysed via SDS-PAGE under reducing 
conditions as illustrated in figure 15. 
 
       
A)            1        2            3           4          5         6          7             8          
            
 
B)              1             2             3             4             5            6             7                    
            
 
Figure 15: Reducing SDS-PAGE (15% acrylamide) illustrating the inclusion body isolation of 
sCD23: A) wild type human sCD23 - 1) peqGOLD protein marker IV; 3) 1
st
 wash; 4) 3
rd
 wash; 5) 2
nd
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wash; 6) 5
th
 wash; 7) 8
th
 wash; 8) purified inclusion bodies, B) mutant sCD23: 1) peqGOLD protein 
marker IV; 2) 1
st
 wash; 3) 2
nd
 wash; 4) 3
rd
 wash; 5) 5
th
 wash; 6) 8
th
 wash; 7) purified inclusion bodies. 
 
A large amount of relatively pure recombinant protein was obtained from the 
inclusion bodies, as shown in figure 15. The expected size of the target protein is 
approximately 25 kDa, and as can be seen in figure 15, the protein band obtained in 
the inclusion body preparation is in the correct size range, present just below the 26 
kDa marker. Figure 15 clearly shows a reduction in contaminating E. coli proteins after 
each wash as well as a minimal loss in sCD23 protein, which was tolerable as each 
wash step improved the purity of the final preparation. The first few washes seemed 
to remove most of the contaminating E. coli proteins whereas subsequent washes did 
not remove large amounts of host protein. In the final step, the eighth wash, it appears 
that very little, if any, contaminants were removed. 
 
The total protein yield of the isolated inclusion bodies was determined to be 200 mg 
from 3 L of culture for the wild type sCD23 protein and 240 mg from 3L culture for the 
mutant CD23 protein. The purified inclusion bodies were solubilised, refolded and 
concentrated according to the method described by Daniels et al. (2005) before further 
purification via gel filtration chromatography.  
 
Figure 16 shows the constant decrease of the redox potential during the refolding 
process, the latter of which indicates whether or not disulfide bonds are being formed 
and thus indicating whether the protein has refolded. The refolding process was 
allowed to continue until the redox potential was below 1 mM, to ensure sufficient 
refolding of the protein. 
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Figure 16: Measurement of redox potential to monitor refolding of wild type and mutant sCD23. 
 
Once the protein was refolded, it was first dialysed against TNC buffer (pH 8) before 
being concentrated to 10 mL using Amicon ultracentrifugal filters. The concentrated 
protein was filtered and further purified via Superdex 75 (26/60) gel filtration 
chromatography, using TNC buffer, at a flow rate of 1 mL/min and injecting 2 mL of 
protein onto the column. The FPLC profiles (Figure 17) demonstrate the purification 
of both the wild type and mutant sCD23 recombinant protein using Superdex 75 gel 
filtration chromatography. Once the relative fractions were eluted from the column, it 
was pooled and concentrated to ± 5 mL using Amicon Ultra filtration centrifugation 
tubes. The total protein concentration was found to be 4.97 mg per 1 L of culture for 
the wild type sCD23 and 2.75 mg per 1 L of culture for the mutant CD23. This 
purified sample was analysed via SDS-PAGE to assess homogeneity, illustrated as an 
inset in figure 17. No contaminating proteins could be observed in the recombinant 
protein-containing fractions as analyzed by Coomassie brilliant blue-stained SDS-
PAGE gels. 
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A) 
 
B) 
 
 
Figure 17: Gel filtration chromatogram of purified CD23 proteins: A) Wild type sCD23 protein 
purification, with the inset showing the purified 25 kDa protein after SDS-PAGE (15% acrylamide) under 
reducing conditions. B) Mutant CD23 (mCD23) protein purification, with the inset showing the purified 
25 kDa protein after SDS-PAGE (15% acrylamide) under reducing conditions. Molecular weight marker 
(peqGOLD protein marker IV) sizes are listed next to each corresponding band of the marker. Each peak 
in the chromatogram represents the different fractions obtained during the purification process and is 
correspondingly labelled. 
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3.3.2 Analysis of the I-domain of CD11b and CD11c 
3.3.2.1 Molecular analyses of the I-domain of CD11 (b and c) 
The CD11 vector construct, which was previously cloned by Nham (1999), was isolated 
and used as template to amplify the vector insert (CD11 I -domain) as illustrated in 
Figure 18. Due to the position of the CD11b encoding region between the BamHI and 
NotI restriction sites (figure 8), we expect to see an insert of approximately 700 bp. 
We expect a similar size for the CD11c I-domain insert. The molecular size marker in 
lanes 6 and 12 (with base pair sizes shown as numbering on the right hand side in the 
figure), identifies amplification in lanes 1, 2, 7 and 8 of a fragment roughly around 
750 bp which suggests a positive result for the amplification of the I-domain for both 
CD11b and CD11c. Lanes 5 and 11 represent negative controls; lanes 3 and 4 indicate 
the uncut isolated plasmid for CD11b and lanes 9 and 10 represent the isolated uncut 
plasmid for CD11c.    
 
                                1      2      3     4      5     6          7     8      9    10    11   12         
                                            
 
Figure 18: DNA Analysis of CD11 I - domain via 1% agarose gel electrophoresis: 1) 2 μL amplified 
CD11b insert; 2) 4 μL amplified CD11b insert; 3) isolated CD11b plasmid; 4) isolated CD11b plasmid; 5) 
CD11b plasmid negative control; 6) DNA base ladder; 7) 2 μL amplified CD11c insert; 3) 4 μL amplified 
CD11c insert; 9) isolated CD11c plasmid; 10) isolated CD11c plasmid; 11) Plasmid negative control; 12) 
DNA base ladder. 
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3.3.2.2 Expression and purification of the I-domain of recombinant CD11 
Transformed cells containing the pGEXCD11bI and pGEXCD11cI plasmids were 
used to express the recombinant αI domain proteins. Figure 19 shows the SDS-PAGE 
gel (15%) of the preparative expression of CD11b and CD11c αI domains under 
reducing conditions. Test expression analyses (results not shown) indicated that the 
desired protein was strongly up-regulated after 2 hours post IPTG induction; hence 
the preparative expression was executed accordingly. In figure 19, it is shown that 
there is clearly up-regulation of a band of protein at approximately 45-50 kDa in lanes 
3 and 6 respectively. This band contains the GST-tagged CD11 I-domain proteins. 
According to Nham (1999) and Daniels (2010), the expected size of the target protein 
is approximately 50 kDa. As can be seen in figure 19, the expressed protein bands are 
in the correct size range, present between the 43 and 55 kDa markers. 
 
                           1                      2                   3                  4                   5                 6                                   
             
 
Figure 19: Analysis of CD11(b+c) preparative expression:  1) peqGOLD protein marker IV; 2) 0 hrs 
induction of CD11 b I-domain; 3) 2 hours post IPTG induction of CD11 b I-domain; 4) peqGOLD 
protein marker IV; 5) 0 hrs post IPTG induction of CD11c I-domain; 6) 2 hours post IPTG induction of 
CD11c I-domain. 
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The αI-domain GST-fusion proteins were then extracted from the bacteria by sonication 
and concentrated before isolation and purification using a GSTrap column and 
Superdex 75 26/60 FPLC column (Amersham Pharmacia Biosciences AB - Uppsala, 
Sweden).  Isolated GST-tagged αI domain proteins were injected onto a GSTrap 
column for purification. Figure 20 shows the elution profile of the CD11αI domains. 
The purification methods for the CD11 (b and c I-domain) proteins were identical and 
therefore the elution profiles look the same. Therefore this figure is representative for 
both the CD11b and CD11c I-domain proteins. The fall-through peak (first peak) 
contains contaminating E. coli proteins. The contaminating proteins were washed off 
the column with equilibration buffer, namely 20 mM Tris-HCl, pH 8 and the second 
peak which contains the GST-tagged αI domain protein was eluted using 10 mM GSH 
in 20 mM Tris-HCl, pH 8. The corresponding tubes were collected, pooled, dialysed 
against PBS, concentrated and analysed with 15% SDS-PAGE under reducing 
conditions to check their purity (inset of Figure 20). However, the total protein yield 
was low for both the CD11b I-domain (on average 1.15 mg per 1L of culture) and the 
CD11c I-domain (0.8 mg per 1L of culture).   
                           
 
 
Figure 20: Elution profile of CD11 I-domain using a glutathione Sepharose column: The inset 
indicates the purified CD11 I domain proteins after SDS-PAGE (15% acrylamide) under reducing 
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conditions along with the molecular weight marker (peqGOLD protein marker IV), with sizes (kDa) 
listed next to each corresponding band of the marker. The columns were equilibrated with 5 column 
volumes of equilibration buffer at 2 mL/minute, before injection of the protein sample onto the column 
at 0.2 mL/minute. The column was washed with 5 column volumes of equilibration buffer, followed by 
elution of the GST-tagged protein with elution buffer at 2 mL/minute. Each peak in the chromatogram 
represents the different fractions obtained during the purification process and is correspondingly 
labelled. 
 
We suspected that the reason for this low protein yield could have been due to the fact 
that the columns that we used had expired and were no longer able to maintain their 
function. Hence we also made use of a GST Spin Purification Kit [Pierce, (USA) 
catalogue no 16106]. Sample application, washing, and elution were performed 
according to manufacturer‘s instructions. The protein yield from this mode of 
purification was much better, with total protein yields ranging from 5.39 mg per 1L of 
culture for the CD11b I-domain and 5.73 mg per 1L of culture for the CD11c I-domain. 
SDS-PAGE (15%) under reducing conditions was used to assess the homogeneity of 
the purified samples from this mode of purification and is illustrated in figure 21.  
 
    1        2           3        4        5         6          7         8                 
 
 
Figure 21: SDS-PAGE analysis of CD11 I-domain proteins after glutathione agarose spin column 
purification. 1) Molecular weight marker (peqGOLD protein marker IV) with sizes (kDa) listed next to 
each corresponding band of the marker; 2) 3
rd
 column wash of CD11b I-domain; 3) CD11b I-domain cell 
lysate supernatant; 5)  CD11c  I-domain cell lysate supernatant; 6) 3
rd
 column wash of CD11c I-domain; 
7) eluted CD11b I-domain/GST fusion protein; 8) eluted CD11c  I-domain/GST fusion protein. 
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Analysis by SDS-PAGE indicated the isolation of highly pure GST fusion protein in 
lanes 7 and 8 (Figure 21).  Furthermore, the purified proteins correspond to the 
predicted sizes of approximately 50 kDa as shown in figure 21 and are also consistent 
with the banding pattern shown in figure 20. However, to further verify that we indeed 
isolated a GST tagged protein, we made use of a Western blot using an anti-GST 
antibody, which is highly specific since it detects only GST fusion protein. Figure 22 
confirms the presence of the GST-CD11 fusion proteins with the arrows indicating the 
relevant GST-proteins. 
      
 
     1     2                         1     2                             1       2               
                                  
 
Figure 22: Western blot analysis of the GST- fusion proteins: Lane 1 - Molecular weight marker 
(peqGOLD protein marker IV) in panels A, B and C, with sizes (kDa) listed next to each corresponding 
band of the marker; Lane 2) CD11c I-domain [panel A]; purified GST protein [panel B] and CD11b I-
domain [panel C] 
 
As figure 22 shows, the CD11 I-domain recombinant protein bands (lane 2 panels A 
and C) are seen between the 43 and 55 kDa protein markers which indicate the 
presence of the target proteins. According to Brockwell et al. (2000), GST has a 
theoretical average molecular mass of 27 000 Da. As depicted in figure 22 (lane 2, 
panel B) the purified GST protein band lies between the 26 kDa and 34 kDa size 
markers which falls within the expected size range for GST.  
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3.4 Conclusion 
The primary purpose of this section was to express and purify recombinant forms of the 
I-domain of CD11 (b and c) as well as sCD23 in its wild type and mutant forms. This 
was successfully achieved by making use of two types of bacterial expression systems 
whereby the pET vector system was used to express the sCD23 (and its mutant) and the 
pGEX-GST fusion system was employed to express the I-domain of CD11b and c. Site-
directed mutagenesis proved an invaluable technique for carrying out the sCD23 
vector modification since it generated sCD23 mutants with greater than 85% 
efficiency in a single reaction. Creation of the sCD23 (25 kDa) expression plasmid 
containing the desired mutation was successfully confirmed by DNA sequencing.  
 
Test expressions (data not shown) indicated that optimal expression of sCD23 and its 
mutant occurred 3 hours after induction with IPTG whereas for the CD11 I-domain 
protein, 2 hours post IPTG induction was favourable. It was also found that Rosetta 
(DE3) E. coli cells typically expressed the CD11 I-domain much better than the BL21 
strain, although we found that over-expression by Rosetta (DE3) strains containing 
the CD11 I-domain insert led to the cell expressing and then placing the protein into 
insoluble bodies or inclusion bodies (data not shown), which is why we found that 2 
hours of protein expression post IPTG induction to be optimal for the soluble CD11 I-
domain. In the case of the wild type sCD23 and its mutant, we discovered that the E. 
coli Rosetta (DE3) expression strain expressed the protein efficiently following 3 
hours of expression post IPTG induction. Since the sCD23 protein is an insoluble 
protein, inclusion bodies first had to be isolated, washed eight times and then refolded 
using the rapid dilution technique. 
 
The purification of the respective proteins was also relatively simple. The glutathione 
S-transferase (GST) Gene Fusion System (which is based on inducible, high-level 
expression of genes or gene fragments as fusions with Schistosoma japonicum GST) 
proved a versatile system for the expression, purification, and detection of the CD11 
I-domain. Expression in E. coli yielded a soluble fusion protein which accumulated 
within the cell‘s cytoplasm. The GST fusion proteins were successfully purified from 
bacterial lysates by affinity chromatography using immobilized glutathione, whereby 
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the GST fusion proteins were captured by the affinity medium and impurities were 
removed by repeated washing. Purified fusion proteins were eluted effectively under 
mild, non-denaturing conditions using reduced glutathione and Western blotting 
further verified that we indeed isolated a GST tagged protein. Gel filtration 
chromatography using a Superdex 75 (26/60) column was found efficient in purifying 
sCD23 and its mutant. SDS-PAGE analyses also illustrated positive identification of 
the respective proteins. At this point, all the respective recombinant proteins were 
now ready for subsequent experiments involving ligand binding studies. 
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4. LIGAND BINDING STUDIES BETWEEN sCD23 AND 
THE I-DOMAIN OF CD11 
 
4.1 Introduction 
Many biological processes depend on a specific interaction between molecules whereby 
the interaction often involves a receptor and a smaller molecule (or a ligand). In another 
sense, a ligand can also be regarded as a signal triggering molecule which binds to a site 
on a target protein. Normally, when a ligand binds to a receptor, the latter often 
undergoes a conformational change which ordinarily initiates a cellular response. 
However, some ligands merely block receptors without inducing any responses 
(Milligan, 2003). Ligand binding comes in many forms and mechanisms. A molecule 
may have a single binding site or many binding sites. If there are multiple binding 
sites, they may be identical or different, for one or many types of molecule. They may 
also be positively or negatively interdependent. Either way, ligand binding is 
complementary and specific for each protein (Nelson and Cox, 2005). 
 
A variety of counter receptors and soluble ligands for β2 integrins and sCD23 have 
already been identified and although it has been found that sCD23 is a natural ligand of  
CD11/CD18, the exact interaction surface between these two very important immune 
modulating proteins has not been characterised well. According to Borland et al. 
(2007), the interaction between sCD23 and another type of integrin, namely the αVβ5-
integrin, promotes growth of pre-B cells, thereby indicating a role in the rescue of 
germinal centre B lymphocytes from apoptosis. As shown in figure 23a, these authors 
mapped the interaction with αVβ5-integrin to an Arg-Lys-Cys motif (RKC) on an 
exposed loop of sCD23, and also found that recognition on the integrin occurs at a site 
distinct from the normal RGD sequence binding site of integrins. However, there does 
not seem to be any data mapping the binding of β2 integrins to CD23. Furthermore, as 
previously demonstrated by Diamond et al. (1993) and Nham (1999), the I-domain of 
the β2-integrins (figure 23b) is involved in ligand binding. We therefore hypothesised 
that the possible site of interaction between sCD23 and CD11/CD18 involves the RKC-
motif located in the lectin head domain of sCD23 and the I-domain of CD11/CD18. 
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Figure 23: Schematic illustration of sCD23 and CD11 possible ligand binding sites: a) A schematic 
diagram of the sCD23 protein is illustrated showing the lectin head and stalk domains; the bolded loop 
and arrow indicates the region of the protein where the RKC-motif recognized by the αVβ5 integrin 
resides (Borland et al., 2007); b) A schematic drawing of the structure of an integrin and its α and β 
subunits (Harris et al., 2000).   
 
In order to confirm that binding does indeed occur between the RKC motif of 
recombinant sCD23 and the I-domain of CD11b and CD11c, we adopted two 
approaches, namely: 
a) ELISA and; 
b) Flow cytometry.  
 
4.1.1 ELISA 
ELISA is the abbreviation of enzyme-linked immunosorbent assay. It is a useful and 
powerful method in estimating ng/mL to pg/mL ordered materials in solution, such as 
serum, urine, sperm and culture supernatant (Savige et al., 1998).  
 
The basic principle of an ELISA is to use an enzyme to detect the binding of antigen 
to antibody whereby the enzyme converts a colourless substrate or chromogen to a 
coloured product, thus indicating the presence of Ag:Ab binding. An ELISA can be 
used to detect either the presence of antigens or antibodies in a sample, depending on 
how the test is designed (Ma et al., 2006). 
 
RKC-
motif 
a) b) 
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For this particular phase of the project we decided to use an ELISA that involved the 
biotin-avidin system. The avidin-biotin system provides a powerful tool for research 
and analysis due to the specific and high affinity (Ka = 10
15
 M 
-1
) interaction between 
avidin (an egg white derived glycoprotein) and biotin (a derivative of vitamin B). 
Biotin-labeled antibodies and enzymes are used as powerful tools in a wide range of 
highly sensitive ―nonradioactive‖ detection systems, where the amount of protein 
needed (nanograms) is extremely low. Such systems are used in standard 
immunological and immunocytochemical techniques and have been used in medical 
applications (Hnatowich et al., 1987). Also, biotinylated derivatives of peptide 
hormones, growth factors and cytokines or other proteins are useful in various research 
applications involving affinity purification of receptors in combination with avidin 
affinity chromatography (Lee et al., 1989). Biotinylation is often performed with N-
hydroxysuccinimide (NHS) esters of biotin or biotinamido hexanoic acid (biotin-AC or 
BAC). The use of the extended spacer arm greatly improves the interaction between 
avidin and the biotinylated macromolecule thus overcoming steric hindrance present at 
the biotin binding sites of avidin (Green et al., 1971). 
 
4.1.2 Flow cytometry using differentiated U937 cells 
Flow cytometry is a technique for counting and examining microscopic particles by 
suspending them in a stream of fluid and passing them by an electronic detection 
apparatus. It allows simultaneous multiparametric analysis of the physical and or 
chemical characteristics of up to thousands of particles per second.  
 
A common variation is to physically sort particles based on their properties so as to 
purify populations of interest. The basic principle entails directing a beam of light 
(most commonly laser light) of a single wavelength onto a hydronamically focused 
stream of fluid. A number of detectors are aimed at the point where the stream passes 
through the light beam: one in line with the light beam (forward scatter) and several 
perpendicular to it (side scatter). Each suspended particle passing through the beam 
scatters the light in some way and fluorescent chemicals found in the particle or 
attached to the particle may be excited into emitting light at a longer wavelength than 
the light source. This combination of scattered and fluorescent light is picked up by 
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the detectors and by analysing fluctuations in brightness at each detector, that is, one 
for each fluorescent emission peak, it is then possible to derive various types of 
information about the physical and chemical structure of each individual particle. 
 
The data generated by flow cytometers can be plotted in a single dimension to 
produce a histogram or in two dimensional dot plots or even in three dimensions 
whereby the regions on these plots can be sequentially separated based on fluorescent 
intensity by creating a series of subset extractions, termed ‗gates‘. The plots are often 
made on logarithmic scales. Signals at the detectors have to be compensated 
computationally as well as electronically because different fluorescent dye emission 
spectra tend to overlap. 
 
For this project we employed flow cytometry using U937 cells in order to determine 
whether the RKC peptide is able to inhibit binding of the wild type sCD23 
recombinant protein to U937 cells which have been differentiated to express CD11. 
  
The U937 cell line is a promonocytic cell line that is one of the only cell lines from 
histiocytic lymphoma that still exhibits most of the monocytic cell characteristics. It 
was isolated from malignant cells of a pleural effusion from a 37 year-old Caucasian 
male with diffuse histiocytic lymphoma (www.ATCC.org). The U937 cell line has 
many characteristics of an immature monocyte and has become a valuable tool for 
studying mononuclear phagocytes in addition to the functional properties of monocytes, 
such as phagocytosis, chemotaxis and cytotoxicity. The expression of many of these 
functions depends on stimulation with differentiating agents (Sheth et al., 1988). 
 
Several differentiation agents have been analysed for their ability to differentiate cells 
and upregulate CD11b cell surface expression. For this study we decided to use vitamin 
D3 as a differentiation agent as it differentiates cells into a monocyte lineage and is able 
to upregulate CD11b and CD11c on the cell surface of these cells (Weber et al., 1995). 
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4.2 Experimental Procedure 
4.2.1. Materials 
Original U937 cells were obtained from Highveld Biological (RSA). Heat inactivated 
foetal calf serum (HI-FCS) and RPMI 1640 growth medium were obtained from 
Hyclone Ltd. (UK). Culture flasks (25 and 75cm
2
) were obtained from Sarstedt 
(USA). Vitamin D3, fibrinogen, Nunc Multi-well plates (clear) and extravidin- 
fluorescein 5'-isothiocyanate (FITC) were obtained from Sigma; anti-CD11b-FITC 
antibody, anti CD11c-phycoerythrin (PE) antibody and the respective isotype controls 
were from Beckman Coulter (Fullerton, California, USA); BSA was from Roche, 
CD23-derived synthetic peptides were from Bachem (Switzerland). All other reagents 
were of analytical grade. 
 
4.2.2 Cell analyses 
4.2.2.1 Cell culture and maintenance 
Cells were routinely maintained in 25 or 75 cm
2
 cell culture flasks in growth medium 
consisting of RPMI 1640 cell culture medium, supplemented with 10% foetal calf 
serum (FCS). The cell lines were maintained between 1 x 10
5
 and 1 x 10
7
 cells/mL. 
The cells were ‗fed‘ by replacing the growth medium every four to five days, by 
aspirating the old medium and resuspending the cells in fresh medium, followed by 
transferring into new 75 cm
2
 flasks, or by simple subculturing of the cells. U937 cells 
were subcultured using a 1:10 split ratio. The cells were grown at 37°C in a 
humidified atmosphere with 5% CO2 and 95% air. 
 
4.2.2.2 Cell counting by Trypan blue 
 
When cells have died, the loss in integrity of the membrane structure allows this stain 
(trypan blue) to enter the cells, where live cells exclude the stain. This results in dead 
cells appearing dark blue whereas live cells appear colourless. Cell counts were 
performed using a Neubauer counting chamber (Superior). Cells were diluted 1:1 with 
trypan blue stain (0.4% w/v trypan blue in PBS).  Each large square of the Neubauer 
counting chamber represents 0.1 mm
3 
and 1 cm
3 
is approximately 1 mL. Therefore the 
total number of cells was determined using the equation:  
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Cells/mL = average cell count per square x dilution factor x 10
4 
4.2.2.3 Cell differentiation  
The upregulation of CD11b on U937 cells is a widely-used marker for differentiation 
into a monocyte lineage. After the differentiation of cells, it was necessary to stain for 
CD11b/c cell surface markers to ensure that the desired cell surface markers had been 
upregulated.  Vitamin D3 (1 μM) was used to differentiate the cells. Cells were cultured 
at 1 x 10
6 
cells per mL and incubated for 24 hours followed by the addition of vitamin 
D3. The cells were subsequently analysed for CD11b/c up-regulation after 72 hours via 
flow cytometry. 
4.2.2.4 Flow cytometric determination of cell surface markers  
Flow cytometry was used to determine whether the U937 cells had been differentiated 
in order to express CD11b or CD11c. This was done by centrifuging an aliquot of the 
cells for 5 minutes at 1000 x g, before resuspending the cells in blocking buffer (1% 
HI-FCS + 1% BSA in PBS, pH 7.4) for 30 minutes at room temperature. Cells were 
centrifuged as before and resuspended at 1 x 10
6
 cells per mL, and stained with 20 μL 
of antibody to the cell surface marker in question. Samples were incubated for 30 
minutes at room temperature in the dark. Cells were centrifuged as before and washed 
thrice with PBS before analysis on the flow cytometer. At the same time, a sample 
was stained with an appropriate isotype control to ensure there was no non-specific 
binding of the antibody to the cells. Cell surface markers detected in this study were 
CD11b (using a CD11b-FITC antibody), and CD11c (using a CD11c-PE antibody).  
A Beckman Coulter FC500 was used for all flow cytometry analysis. During each 
experiment, it was ensured that a consistent number of cells was used and a minimum 
of 10 000 events was counted per sample. The mean fluorescence intensity was used 
to compare samples. 
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4.2.2.5 Flow cytometric determination of ligand binding and peptide inhibition  
Differentiated cells, at a density of 1x10
6 
cells/mL, were centrifuged at 1000 x g for 5 
minutes followed by removing the supernatant and adding blocking buffer. The cells 
were blocked for 30 minutes at room temperature followed by rinsing the differentiated 
cells twice with PBS and resuspending at 1x10
6 
cells/mL in fresh growth medium. 
Fibrinogen, the recombinant CD23 proteins and the custom synthesized peptides (all of 
which were biotin labelled – described in section 4.2.3.2) were made up to 200 ng/mL 
in fresh growth medium and 200 μL was aliquotted into Beckman Coulter flow 
cytometry tubes, along with a control tube where PBS instead of protein was added. 
Fibrinogen was used as a positive control, since it is known that it binds CD11b and 
CD11c (Nham, 1999; Zhou et al. 1994). An equal volume of evenly resuspended cells 
was added to each tube (resulting in a final protein concentration of 100 ng/mL) and 
incubated for one hour at 37 °C. At the end of the incubation, unbound protein or 
peptide was removed by washing twice with PBS, pH 7.4.  Extravidin-FITC at a 1:200 
dilution was added and further incubated with the cells at room temperature in the dark 
for 1 hour. Consequently, cells were rinsed thrice with PBS and resuspended in fresh 
RPMI medium. Appropriate solvent vehicle controls (e.g. PBS, pH 7.4 and 0.1% 
trifluoroacetic acid [TFA]) were also performed. 
 
For peptide inhibition experiments, the RKC and AAC biotin labelled peptides (2 μM) 
were added to the cells in the presence of unlabelled wild type sCD23 and incubated for 
90 minutes at 37 °C before staining with Extravidin-FITC.   
 
4.2.3 Peptide biochemistry 
4.2.3.1 Design of custom synthesized peptides 
A set of overlapping peptides encompassing residues 170 to 179 of the 25 kDa sCD23 
sequence was synthesized by Bachem (Switzerland). Each peptide was synthesized 
comprising a unique CD23-derived decapeptide sequence, plus a common N-terminal 
tetrapeptide extension (SGSG) to which a biotin moiety was attached (i.e. biotin-
SGSG-X10 where X10 is the specific CD23-derived decapeptide sequence). The C-
terminal residue was amidated. The specific peptide sequences were: 
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1)  Biotinyl-Ser-Gly-Ser-Gly-Phe-Gln-Arg-Lys-Cys-Tyr-Tyr-Phe-Gly-Lys-NH2 (also 
referred to as the RKC peptide in this text), 
2) Biotinyl-Ser-Gly-Ser-Gly-Phe-Gln-Ala-Ala-Cys-Tyr-Tyr-Phe-Gly-Lys-NH2 (also 
referred to as the AAC peptide in this text). 
 
4.2.3.2 Biotinylation of proteins 
For biotin labelling, a biotin labelling kit (Sigma) was used and instructions followed 
according to manufacturer‘s instructions. Briefly, the biotin reagent (biotinamido 
hexanoic acid 3-sulfo-N-hydroxysuccinide ester or BAC-SulfoNHS), was dissolved in 
DMSO and 0.1 M sodium phosphate buffer to a final concentration of 5 mg/mL. This 
reagent was added to the relevant test samples at a molar concentration ratio of 13:1 
of BAC-SulfoNHS reagent to protein and incubated for 1 hour at room temperature 
before removal of the unlabeled biotin via centrifugation with Amicon Ultra filtration 
centrifugation tubes.  The concentration of the biotin labelled samples was determined 
via the BCA assay. A dot blot was executed to verify that the relevant proteins were 
biotinylated. 
 
4.2.3.3 Dot blot procedure 
For dot blotting, a piece of Immobilon PVDF membrane was pre-wet in 5 – 10 mL 
100% methanol for 5 seconds followed immediately with soaking in 500 mL dH2O 
for 10 minutes to remove the methanol. The membrane was equilibrated for 10 
minutes in PBS. Proteins were dotted onto PVDF membrane using a pipette, and the 
membrane dried at 37 °C for 5 minutes. After drying, the membrane was blocked in 
PBS (pH 7.4) containing 1% (w/v) BSA for 30 minutes. After rinsing twice with PBS, a 
1:10 000 dilution of avidin-conjugated horse-radish peroxidase (Extravidin, Sigma) in 
PBS, was added to the membrane and incubated for 30 minutes at room temperature. 
Incubation was followed by washing once for 10 minutes and 3 times for approximately 
1 minute with PBS. Detection was carried out by adding TMB (3,3‘,5,5‘ – tetramethyl-
benzidine liquid substrate, Sigma, catalogue number T4444). The reagent was allowed 
to incubate until colour developed, where the reaction was stopped by adding ddH2O. 
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4.2.4 ELISA analyses  
The recombinant wild type sCD23 protein, its mutant and the custom synthesized 
peptides from section 4.2.3 were used to assay binding affinity for recombinant CD11 
via ELISA. 
 
GST-CD11 (b or c I-domain) fusion protein at a concentration of 5 μg/mL in PBS was 
added to each well (50 μL) on Nunc maxisorp 96-well microtiter plates and incubated 
overnight at 4 ºC. Plates were washed with PBS and blocked overnight with Pierce® 
Protein-Free (PBS) Blocking Buffer (catalogue no. 37572), followed by rinsing three 
times with PBS. Fibrinogen was used as a positive control, since it is known that it 
binds CD11b and CD11c at their αI domains (Choi and Nham, 2002). Hence, biotin-
labelled wild type sCD23 and mutant sCD23 proteins, the RKC and AAC peptides, as 
well as fibrinogen were added separately to 96-well maxisorp plates (at varying 
concentrations ranging from 0.156 to 5 μM, 50 μL) in binding medium (140 mM 
NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, 1 mM CaCl2 and 1 mM 
MgCl2, pH 7.4). The biotin labelled peptides and proteins were incubated for 4 hours 
at 4 ºC. Plates were washed four times with PBS to remove unbound biotinylated 
proteins, followed by loading corresponding wells with 100 μL of a 1:10 000 dilution 
of avidin-conjugated horse-radish peroxidase (Extravidin, Sigma) and incubating 
plates further at room temperature for 1 h.  Plates were washed 5 times with PBS to 
remove any unbound Extravidin and TMB substrate was added. Once a blue colour 
had developed, the reaction was stopped using 50 μL of a 1 N solution of sulphuric acid 
before reading at 450 nm using a Multiscan MS microplate reader (Labsytsems). The 
amount of binding was plotted using GraphPad Prism software and binding curves were 
fitted to the data using a one-site specific binding nonlinear fit model. 
 
4.2.5 Peptide competition analyses via ELISA 
To further characterize the moiety of wild type sCD23 recognized by the CD11 (b and 
c) I-domain and binding specificity, a competitive binding experiment was carried out 
with sCD23 derived synthetic peptides. 
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GST-CD11 (b or c I-domain) fusion protein was coated onto Nunc maxisorp 96-well 
microtitre plates as described in section 4.2.4. Separate CD11 (b or c) I-domain coated 
wells were incubated with excess unlabelled wild type sCD23 (10 μM) in the presence 
of 0.6 μM biotin labelled RKC peptide or AAC peptide (50 μL in binding medium) for 
4 hours at 4 ºC. Plates were washed four times with PBS to remove unbound proteins 
and peptides, followed by detection of biotin-labelled peptides with Extravidin-HRP 
and TMB substrate. Wells representing negative controls contained CD11 I-domain 
and PBS only. 
 
Similarly, a reciprocal experiment was attempted in which the CD11 I-domain was 
incubated with 0.6 μM unlabelled wild type CD23 and 10 μM biotin labelled RKC or 
AAC peptide. We then compared the signal obtained from this interaction, to that of 0.6 
μM (biotin labelled) wild type CD23 incubated with CD11 only. This was done because 
we did not have unlabelled RKC or AAC peptide to work with and also, we wanted to 
establish if the CD23-CD11 interaction was in any way affected in the presence of 
excess RKC or AAC peptide. 
  
4.2.6 Statistical analysis 
Analysis of data was performed using GraphPad Prism v5.0 software (GraphPad 
Software Inc., San Diego, C.A., U.S.A). All data are reported as mean ± SD for 
triplicate experiments. Non parametric grouping of data was analyzed by ANOVA and 
secondary data analysis for significance with Tukey post–tests. Group comparisons 
were deemed significant for two-tailed P < 0.05. 
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4.3. Results and Discussion 
4.3.1 Dot blot of biotinylated proteins 
A dot blot was executed to verify that the relevant proteins were biotinylated (Figure 
24), clearly illustrating that the relevant proteins were successfully labelled with 
biotin. 
 
           sCD23         mCD23     FIBRINOGEN      RKC         AAC 
                        
     
Figure 24: Dot blot of biotinylated proteins and CD23-derived peptides. 
 
4.3.2 Cell binding studies 
4.3.2.1 Flow cytometric analysis of cell surface markers 
CD11/CD18 was upregulated on U937 cells by differentiation with vitamin D3 for 72 
hours. Figure 25 illustrates a dot plot of two cell populations observed after 
differentiation of U937 cells with vitamin D3 and Figure 26 illustrates histogram 
overlays showing CD11b/c upregulation.  
 
   
Figure 25: Flow cytometric analyses of U937 cells after differentiation with Vitamin D3. The dot 
plot generated via flow cytometric analysis indicated two different populations. Data are representative 
of one experiment performed in duplicate, representative of two others.    
 
 
population #1 
 
population # 2 
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With reference to figure 25, the dot plot indicated two different populations, whereby 
after gating the data, it was determined that population number 2 seemed to express 
both CD11b and CD11c cell surface markers whereas population number 1 expressed 
extremely low levels or none at all of  these cell surface markers. 
 
Furthermore, according to figure 26, the increase in mean fluorescence intensity of cells 
stained with mAbs specific for CD11b and CD11c indicates that the cell surface 
markers in question were up-regulated after addition of vitamin D3.  
 
Figure 26: Flow cytometric determination of cell surface markers. U937 cells were stained with 
mAbs specific for CD11b and CD11c. CD11b cell surface markers were detected using a CD11b-FITC 
antibody (in channel FL1) and CD11c cell surface markers were detected using a CD11c-PE antibody 
(in channel FL3). Isotype control staining is indicated by the blue line, the red line indicates cells 
stained with a mAb specific for CD11b and CD11c (as indicated in respective panels) and the shaded 
area indicates unstained cells. Data was gated for population 2 only and are representative of one 
experiment performed in duplicate representative of two others. 
 
4.3.2.2 Flow cytometric determination of ligand binding  
Differentiated cells were incubated with biotin labelled CD23 derived peptides, 
fibrinogen as a positive control and with PBS as a negative control. Those cells which 
were able to bind to the biotin-labelled peptides were visualised using extravidin-FITC 
and analysed via flow cytometry. Figure 27 illustrates histogram overlays of the 
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interaction between these different peptides/proteins and U937 cells expressing 
CD11b/c.  
 
According to figure 27 (and as compared to the negative control in panel 6) the increase 
in mean fluorescence intensity of cells incubated with the different peptides/proteins 
indicates that there was definitely an increase in peptide binding to the cells. In panels 
1, 2 and 5, it is noted that there is an interaction between the cells and the sCD23, the 
RKC peptide and fibrinogen (used as positive control). This is in contrast to panel 3, 
where the interaction between the CD11 expressing cells and the mutant sCD23 is 
greatly attenuated; implying the cells failed to bind to the mutant sCD23. In panel 4, the 
interaction of the AAC peptide with the differentiated U937 cells is also greatly reduced 
when compared to the positive interaction that we see in panels 1, 2 and 5. Therefore, 
this could also suggest that the cells failed to bind the AAC peptide. 
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   1) Wild type CD23 
   
      2) Peptide FQRKCYYFG 
   
3) Mutant CD23 
   
4) Peptide FQAACYYFG 
   
  5) Fibrinogen 
   
 6) Control 
   
 
Figure 27: Histogram overlays of the interaction between the different CD23 peptides/proteins and 
U937 cells expressing CD11b/c. For each histogram that was gated on population 2, the shaded area (in 
panels 1-5) represents the control (differentiated U937 cells in the absence of peptide/protein and stained 
with extravidin-FITC alone) whereas the unshaded area represents differentiated U937 cells that were 
incubated with the respective biotin labelled peptide/protein. Panel 6 demonstrates non-specific binding 
where the shaded area represents unstained differentiated U937 cells (in the absence of any 
peptide/protein) and the green line represents differentiated U937 cells (in the absence of any 
peptide/protein) that were stained with extravidin-FITC. Data are representative of one experiment 
performed in duplicate, representative of two others. 
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According to Diamond and Springer (1993) and Oxvig et al. (1999), the CD11 I-
domain blocking antibody CBRM1/5, impedes CD11b-dependent adhesion to 
fibrinogen and ICAM1. Therefore, in order to prove that differentiated cells bound 
sCD23 derived proteins through an interaction with CD11b; the cell binding studies 
were repeated in the presence of this blocking antibody (CBRM1/5). 
  
Table 2 and figure B2 (addendum 8.2) shows the binding experiments repeated in the 
same manner, but with the CBRM1/5 blocking antibody pre-incubated with the cells 
for each ligand in addition to the unblocked cells. The data show a decrease in mean 
fluorescence intensity in the presence of the blocking antibody; which implies that the 
CD11b α I-domain blocking antibody is able to inhibit binding of the sCD23 protein 
as well as the RKC peptide and fibrinogen to the cells. Hence these data confirm that 
binding of sCD23 and the RKC peptide to CD11b expressing cells does involve the 
CD11b I-domain. 
 
Table 2: Mean fluorescence intensity ± S.D. for CD11b/c expressing (U937) cells 
with CD23 proteins and fibrinogen in the absence/presence of CBRM1/5. Measured 
fluorescence intensities were determined from three experiments performed in 
triplicate. 
 
Protein Mean fluorescence intensity ± S.D. 
 
Wild type sCD23 1.61 ± 0.02 
Fibrinogen 1.61 ± 0.09  
RKC peptide 1.87 ± 0.12 
Wild type sCD23 + CBRM1/5 1.52 ± 0.03 
Fibrinogen + CBRM1/5 1.38 ± 0.11  
RKC peptide + CBRM1/5 1.65 ± 0.04 
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4.3.2.3 Flow cytometric determination of peptide inhibition 
Biotin labelled RKC or AAC peptide (2μM) was incubated with differentiated U937 
cells in the presence of unlabelled wild type sCD23 to determine if these synthetic 
peptides were able to inhibit sCD23 binding to the CD11b/c expressing cells (Figure 
28).  
 
It is evident from figure 28 that the RKC peptide seemed to compete with the wild 
type sCD23 for binding to CD11 expressing cells since the binding of sCD23 to the 
U937 cells was noticeably attenuated in the presence of excess RKC peptide as 
compared to the differentiated cells incubated with biotin labelled sCD23 only. This 
could also imply that the RKC peptide and the sCD23 protein are competing for the 
same binding site on CD11.  
 
 
 
 
Figure 28: Flow cytometric analyses of peptide inhibition on U937 cells expressing CD11b/c. 
Differentiated U937 cells were incubated with excess concentrations of biotin labelled RKC peptide in 
the presence of unlabelled wild type sCD23 and detected with extravidin-FITC and flow cytometry. 
This histogram was gated for population 2 only. The green line represents biotin labelled sCD23 (100 
ng) in the absence of any peptide, the shaded area represents excess (2 μM) RKC peptide incubated in 
the presence of unlabelled sCD23 (100 ng) and the purple line represents the negative control. Data are 
representative of one experiment performed in duplicate representative of one other.  
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4.3.3 ELISA analyses 
4.3.3.1 Determination of ligand binding via ELISA 
After coating ELISA plates with CD11b/c-GST fusion proteins at a concentration of 5 
µg/mL and an overnight incubation at 4 ºC, plates were washed with PBS and blocked 
with Pierce® Protein-Free (PBS) Blocking Buffer overnight at 4 ºC. This was 
followed by washing each plate thrice with PBS and interacting separately with 
recombinant biotin labelled sCD23, mutant sCD23, fibrinogen as well as the synthetic 
sCD23 derived peptides at varying concentrations ranging between 0.156 and 5 μM. 
The data obtained from the ELISA was used to produce binding curves (illustrated in 
figure 29) using a one site binding model in Graphpad Prism 5 software. Table 3 
shows the binding affinities during separate experiments of the CD11b and CD11c αI 
domain proteins for CD23 proteins and fibrinogen. 
 
Table 3: Equilibrium dissociation constants for CD11b/c αI domain interaction with 
CD23 proteins and fibrinogen. Measured affinities [Kd (μM) ± S.D.] were determined 
from three experiments performed in triplicate. 
 
Protein / Peptide CD11b α I-domain  
 
CD11c α I-domain  
Fibrinogen 0.16 ± 0.04 0.21 ± 0.03  
Wild type sCD23 0.36 ± 0.14 0.39 ± 0.09 
Mutant sCD23 No binding No binding 
RKC peptide 1.75 ± 0.66 1.53 ± 0.72 
AAC peptide No binding No binding 
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Figure 29: Saturation binding curves (representing specific binding) of the respective proteins 
with the CD11 I-domain.  Each purified (CD11b/c) protein (5 μg/mL) was added to wells in microtiter 
plates (50 μL) and incubated with biotin-labelled proteins and sCD23 derived synthetic peptides (at 
varying concentrations) in binding medium followed by detection with Extravidin-HRP and TMB 
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substrate. Data are representative of the means ± SD of 3 independent experiments performed in 
triplicate. 
 
Figure 29 illustrates binding of these different recombinant proteins and peptides to the 
I-domain of CD11b and CD11c. PBS was used as a negative control. This figure 
indicates that the I-domain of both CD11b and CD11c is able to bind fibrinogen, wild 
type CD23, and the RKC peptide in a statistically significant manner when compared to 
the mutant sCD23 and the AAC peptide.  Both the mutant and the AAC peptide (results 
not shown) failed to bind to the CD11b/c I-domain.  
 
In order to prove that the CD11 I- domain protein is able to function as a distinctive unit 
without any inhibitory effects by the fused GST protein, we coated microtitre plates 
separately with GST-CD11bI, GST-CD11cI and GST. These plates were incubated 
with biotin labelled sCD23, mutant CD23, fibrinogen, RKC peptide and the AAC 
peptides and detected with Extravidin and TMB substrate. Figure 30 reveals that the 
wild type CD23, fibrinogen and the RKC peptide bound to the CD11b/c I-domain but 
not GST. However, specific binding data for the mutant CD23-CD11 and the AAC-
CD11 interaction were all zero, implying that the peptide failed to bind to either the 
GST moiety or the CD11-GST recombinant protein. These findings therefore suggest 
that the CD23-derived proteins and fibrinogen are able to bind to the CD11b/c I-domain 
itself. Previous reports by Griggs et al. (1998) and Kamata and Takada (1994) 
corroborate our evidence that the GST portion of the recombinant protein does not 
inhibit the target protein interaction.  
 
With reference to table 3, it is apparent that the CD11b/c I domain has a higher 
affinity for the wild type sCD23 than the RKC peptide. Also these data corroborate 
the data from figure 30, which shows that an interaction between the RKC peptide / 
sCD23 / fibrinogen proteins and CD11b/CD11c occurs through the αI domain of the 
integrins.  There seemed to be very little difference in the affinities of the wild type 
sCD23 protein for the CD11b I-domain (0.36 ± 0.14 μM) and the CD11c I-domain 
(0.39 ± 0.09 μM). The dissociation constants for CD23-CD11b/CD18 and CD23-
CD11c/CD18 are comparable to those determined by Daniels (2010). 
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In addition, the sCD23-CD11 Kd values were higher than what was seen for 
fibrinogen interaction with CD11b (Kd 0.16 ± 0.04 μM) and CD11c (Kd 0.21 ± 0.03 
μM). The Kd values for the CD11b/c-fibrinogen interaction were similar to published 
data by Zhou et al., (1994) (0.22 ± 0.07 μM). 
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Figure 30: Specific binding of CD11b/c I-domain to CD23 derived proteins and fibrinogen. Each 
purified CD11b/c I-domain protein or GST (5 μg/mL) was added to wells in microtiter plates and 
incubated with the respective biotin-labelled protein (0.6 μM) in binding medium and detected with 
Extravidin-HRP and TMB substrate. Data shown are means ± SD of 3 experiments performed in 
triplicate and asterisks represent significant differences compared to GST where (***) is equivalent to P < 
0.0001; (**) is equivalent to P <  0.001; (*) is equivalent to P < 0.01. 
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4.3.3.2 Peptide inhibitory analyses via ELISA 
A competitive binding experiment was carried out with sCD23 derived peptides. In 
this section our aim was to compare the CD23-CD11 or peptide-CD11 interaction with 
and without the excess competitor. Therefore, 0.6 μM biotin labelled RKC or AAC 
peptide was incubated with recombinant CD11 in the presence of an excess 
concentration of unlabelled wild type CD23. Similarly, excess concentrations (10 μM) 
of the biotin labelled RKC or AAC peptide were incubated with 0.6 μM unlabelled 
wild type sCD23 to determine if its binding to GST-CD11b/c I-domain (Figure 31) 
was in any way influenced. 
 
 
The results were expressed as percentage binding, derived from the following 
formula:  
 
 (%) binding = [(ODTS / ODneg × 100) – 100] 
 
where ODTS = OD450nm of the test sample and ODneg = OD450nm of the negative 
control.  
 
It is evident from figure 31 that excess wild type (unlabelled) sCD23 seemed to 
inhibit the CD11b/c I-domain-RKC interaction considerably. Likewise, in the 
reciprocal experiment, an excess RKC peptide concentration seemed to inhibit the 
wild type sCD23-CD11 interaction albeit to a lesser degree. This result indicates that 
the RKC peptide and sCD23 compete for the same binding site on the CD11 I-domain 
although it does seem that the integrin has a higher affinity for the sCD23 protein, 
which further validates the data from the cell studies. Furthermore, with regards to the 
interaction between the CD11b/c I domain-AAC peptide in the absence or presence of 
unlabeled sCD23 (data not shown), the signal obtained was similar to that of the 
negative control. Hence, it is deduced that the AAC peptide has no effect on the 
sCD23-integrin interaction. 
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Figure 31: Peptide inhibitory analyses with the I-domain of CD11b/c. Microtiter plates coated with 
GST-CD11b I-domain were prepared as described under Materials and Methods. An excess 
concentration (10 μM) of biotin labelled RKC peptide was incubated with 0.6 μM unlabelled wild type 
sCD23 and detected with Extravidin-HRP and TMB substrate. This interaction was compared to that of 
0.6 μM labelled wild type CD23 (in the absence of any peptide) with the I-domain of CD11. A 
reciprocal experiment was also performed where 10 μM unlabelled wild type sCD23 was incubated 
with 0.6 μM biotin labelled RKC peptide and detected accordingly. The signal from the latter 
interaction was compared to that of 0.6 μM biotin labelled RKC (in the absence of any peptide) with 
the I-domain of CD11. PBS was used as a negative control. Data are representative of the means ± SD 
of 3 independent experiments performed in triplicate. Asterisks represent significant differences 
compared to the negative control where (***) is equivalent to P < 0.0001; (**) is equivalent to P <  0.001; 
(*) is equivalent to P < 0.01 and n.s. means not significant. 
 
4.4. Conclusion 
In this section we investigated the interaction surface between sCD23 and the ß2 
integrins CD11b and CD11c. According to Borland et al. (2007), the interaction 
between sCD23 and the αVβ5-integrin involves an Arg-Lys-Cys motif (RKC) located 
in a small disulfide-bonded loop at the N-terminal end of the C-type lectin domain 
region of the sCD23 molecule. However, there does not seem to be any data mapping 
the binding of β2 integrins to sCD23. Furthermore, since it was shown by various 
authors that the I-domain of beta integrins is involved in ligand binding, we set out to 
 
 92 
prove that the binding of β2 integrins to sCD23 involved the integrin αI-domain and the 
RKC motif of sCD23.  
 
We decided to determine the binding analyses via ELISA between a recombinant form 
of the I-domain of CD11b/CD11c and a recombinant form of sCD23, as well as a 
mutant form of sCD23, where alanine residues replace the basic arginine and lysine 
residues in the RKC motif. Custom synthesized decapeptides, one containing the RKC 
motif of the wild type sCD23 molecule and the other, a mutant version (similar to the 
mutant sCD23 protein) of this decapeptide were also used in the ELISA analyses. 
Another approach that we employed was to determine ligand binding analyses via flow 
cytometry using U937 cells which were differentiated to express CD11b/c on the cell 
surface and incubating these cells with the wild type and mutant biotinylated sCD23 
proteins or peptides. 
 
Flow cytometry analyses showed that wild type sCD23, the RKC peptide and 
fibrinogen (the latter of which is known to bind to CD11b and CD11c, according to 
Zhou et al., 1994 and Nham, 1999) bound differentiated U937 cells. The mutant sCD23 
and the AAC peptide failed to bind. This suggests that the integrin recognizes the RKC 
motif as a binding site on the sCD23 protein.  
 
To further characterize the moiety of sCD23 recognized by CD11b/c and binding 
specificity, a competitive binding experiment was carried out. The differentiated 
U937 cells were incubated with an excess concentration of biotinylated RKC peptide 
or AAC peptide in the presence of unlabelled native sCD23.  Data from figure 28 
showed that excess concentrations of the RKC peptide competitively inhibited 
binding of sCD23 to differentiated U937 cells whereas the AAC peptide (and based 
on data from figure 27) had no effect since it failed to bind to the CD11b/c expressing 
cells.  
 
According to Diamond and Springer (1993) and Oxvig et al. (1999), the CD11 I-
domain blocking antibody CBRM1/5, impedes CD11b-dependent adhesion to 
fibrinogen and ICAM1. Therefore, in order to prove that differentiated cells bound 
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sCD23 derived proteins through an interaction with CD11b; the cell binding studies 
were repeated in the presence of this blocking antibody (CBRM1/5). Interestingly, 
these studies (table 2 and figure B2) have shown that sCD23 and the RKC peptide 
bind cells that have the β2 integrin proteins up-regulated on their cell surface and that 
this binding is significantly diminished by an anti-CD11b antibody specific for the αI 
domain.  
 
The ELISA data further supported the cell binding data and showed binding of 
CD11b/c αI domain to sCD23 and the RKC decapeptide but not to the mutant sCD23 
and the AAC decapeptide. Kd values from table 3 showed that the affinity of the CD11b 
and CD11c I domain for the wild type sCD23 (0.36 ± 0.14 and 0.39 ± 0.09 μM) was 
much higher as compared to its affinity for the RKC decapeptide (1.75 ± 0.66 and 1.53 
± 0.72 μM).  A competitive binding experiment also showed that excess sCD23 was 
able to partially inhibit binding of biotinylated RKC decapeptide to recombinant GST-
CD11b/c I-domain. Furthermore, it was found that excess concentrations of this RKC 
peptide only slightly inhibited binding of wild type sCD23 to the integrin. Maybe it is 
possible that the proteins are binding to additional sites on the β2 integrin proteins.  
 
Moreover, in order to demonstrate that the GST-moiety (attached to the CD11 I-domain 
that was used for the ELISA binding studies) had no effect on protein binding we 
decided to incubate the proteins of interest with purified GST at varying concentrations. 
Data from figure 30  further substantiate our findings that fibrinogen, wild type sCD23 
and the RKC peptide bound to GST-CD11b/c I-domain but not GST itself, suggesting 
that these proteins are able to bind to the CD11b/c I-domain only.  In contrast, no 
interaction was observed between the mutant sCD23 and GST nor the CD11b/c I-
domain and similarly so for the AAC peptide. 
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5. CONCLUSIONS AND RECOMMENDATIONS FOR 
FUTURE STUDIES 
 
From this study it can be concluded that the I-domain of recombinant CD11b and 
CD11c were successfully expressed and purified. In addition, two recombinant forms 
of soluble CD23, namely a wild type and site directed mutant, were also effectively 
expressed and purified. The mutant sCD23 was successfully confirmed by DNA 
sequencing. For expression of the CD11 I-domain, the E. coli BL 21 (DE3) 
expression strain was established as the most efficient strain tested whereas for 
expression of sCD23, the E. coli Rosetta (DE3) expression strain was established as 
the most efficient strain tested following 3 hours of expression. SDS-PAGE analysis 
illustrated positive identification of expression of the wild type and mutant sCD23 (25 
kDa) proteins respectively and similarly so for the CD11 proteins. Gel filtration 
chromatography using a Superdex 75 (26/60) column was found efficient in purifying 
sCD23 and affinity chromatography proved highly effective in purifying recombinant 
CD11b and CD11c. 
 
Ligand binding studies, analysed via flow cytometry have shown that sCD23 binds 
differentiated U937 cells that have the β
2 
integrin proteins upregulated on their cell 
surface. In addition, similar to findings by Daniels (2010), we found that this binding is 
significantly diminished by an anti-CD11b antibody specific for the αI domain which 
suggests that the I-domain is possibly a major recognition site between sCD23 and 
CD11b and perhaps CD11c.  The data also demonstrate that the integrins recognize a 
basic domain on CD23; known as the RKC motif. This RKC motif recognized by the 
β2 integrins is located at positions 172–174 of the human CD23 protein and is 
preserved in all forms of sCD23 that possess cytokine activity (Gould et al., 2003). 
 
Figure A1 (Addendum 8.1) places the RKC motif in the context of its general position 
in the CD23 protein and demonstrates that the RKC-centred integrin binding site is 
completely separate from those used to capture either IgE or CD21 (Hibbert et al., 
2005). It is also separate from the sequence in the stalk region reported to bind to 
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major histocompatibility complex class II molecules (Grimbacher et al., 2002). The 
finer detail provided by the NMR structure of derCD23 (Hibbert et al., 2005) and 
crystal structure of sCD23 (Wurzburg et al., 2006) locates the RKC in a small 
disulfide bonded loop near the N-terminal end of the lectin domain at a solvent-
exposed tight turn between the β0 and β1 strands, with the side chain of Cys174 
participating in formation of a disulfide bond with Cys
163
, as shown in figure A1. The 
data from the ELISA and cell binding studies showing loss of binding and activity of 
peptide AAC (where alanine groups replace the basic arginine and lysine residues) are 
consistent with a role for this solvent-available basic site. According to Borland et al. 
(2007), the crystal structure of sCD23 and the NMR structure of derCD23 do show 
striking differences, and in the specific case of the RKC motif, both Arg
172
 and Lys
173
 
are clearly exposed to the solvent in the derCD23 structure (Figure A1(D), gray 
lines), whereas the sCD23 crystal structure shows Lys
173
 occupying a less solvent-
available position close to the α-1 helix and the arginine in a different but still 
exposed position (Figure A1(D), blue lines, and Figure A1(B), panels ii and iv). 
However, although binding of calcium causes notable conformational changes in the 
structure of sCD23 as a whole (Wurzburg et al., 2006), Borland et al. (2007) reported 
that there is relatively little effect on the orientations and relative positions of the 
RKC residues in the calcium-free and bound states [shown in figure A1 (E)] 
 
In vitro studies also showed that CD11 was able to bind wild type CD23 but not the 
mutant sCD23. Similarly, CD11 was able to bind the RKC peptide but not the AAC 
peptide which further emphasizes the importance of the RKC motif in the CD23-
CD11 interaction.  
 
The ELISA data further supported the cell studies which showed binding of CD11b and 
c α I-domain to wild type sCD23, the RKC peptide and fibrinogen. Fibrinogen was used 
as a positive control since it is known that it binds CD11b and CD11c at their αI 
domains (Choi and Nham, 2002). The binding studies have shown that sCD23 proteins 
bind the αI domain of CD11b and CD11c, however; according to Daniels (2010), this 
does not rule out the possibility that the proteins could bind to additional sites on the β
2 
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integrin proteins since other ligands for β
2 
integrin proteins have been shown to bind to 
other sites in addition to the αI domain of integrins. For instance, Zymosan is also able 
to bind CD11b through one or more lectin sites found outside of the I domain (Thornton 
et al., 1996). Furthermore, according to Zhou et al. (1994) the α-I domain is only 
minimally implicated in the binding of Factor X to CD11b.  
 
The data also demonstrate the importance of the RKC motif in ligand binding between 
sCD23 and the β
2
integrins, since a loss of binding and activity was observed when the 
mutant CD23 or AAC peptide interacted with the CD11b or CD11c integrins. Peptide 
inhibitory analyses further support the finding that the RKC motif acts as a prerequisite 
in the CD11-sCD23 interaction since excess concentrations of the RKC peptide 
inhibited the sCD23-CD11 interaction. Likewise, it was determined that excess 
concentrations of sCD23 considerably attenuated the RKC peptide-CD11 interaction. 
These data are comparable to reports by Borland et al. (2007) where their study 
identifies the αVβ5 integrin as a CD23 receptor and also defines the RKC-motif as the 
major recognition site for the integrin on the CD23 protein. 
 
Disappointingly, the fact that the mutant version of CD23 failed to interact with CD11 
could also possibly be due to the modification of the RKC motif. Since we changed 
the primary structure of the CD23 protein it is possible that we unavoidably created a 
different but also inactive protein. This flaw could have been addressed by conducting 
ligand binding studies to other ligands such as IgE or CD21 to show that the mutant 
CD23 protein was biologically active. 
 
Using an ELISA to obtain binding kinetics is not a very sensitive method to use; 
however, it was able to confirm that the binding is occurring as we predicted. Further 
study into the interaction between these proteins using more sensitive binding analysis 
methods could further expound their interaction sites. Site directed mutagenesis of the 
sCD23 proteins was also useful to elucidate which parts of the CD23 proteins are 
binding the CD11b and CD11c integrins. 
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Surface plasmon resonance spectroscopy or SPR analysis, could prove a highly 
sensitive method to study the kinetics encompassing the binding between CD11 and the 
recombinant forms of sCD23. It is an optical technique used for the detection of two 
different molecules in which one is mobile and one is fixed on a thin gold film. Binding 
of the mobile molecule or analyte to a molecule fixed on the gold film changes the 
refractive index of the film which can be quantified with precision. Binding affinities 
can be determined from the ratio of rate constants, yielding a straightforward 
characterization of protein-protein interaction. SPR directly detects mass 
(concentration) with no need for fluorescent or radioactive labelling of polypeptides 
before measurement (Drescher et al., 2009). 
 
Other more sensitive techniques that we can employ for future studies could also 
include QCM or Quartz Crystal Microbalance technology. QCM is a sensitive balance 
capable of measuring changes in mass on a molecular level. An applied AC-potential 
causes the quartz crystal to vibrate at a resonance frequency which changes as 
molecules flown over the crystal bind to the surface. This difference in frequency is 
then used to characterize a label-free molecular interaction in real time. Furthermore, 
QCM technology can be used to analyse a wide range of biomolecules and 
macrostructures as diverse as cells, bacteria, viruses, proteins and antibodies. 
Interactions can even be measured directly in a crude matrix, which is beneficial, since 
the analytes do not have to be purified, thereby giving results that are close to what 
would happen in the body. (http://www.attana.com). 
 
Future studies could possibly involve analyses of the interaction surface between the 37 
kDa and 16 kDa variant of CD23 and CD11b/c via site directed mutagenesis and QCM 
technology. It would also be interesting to determine the cellular response initiated 
following ligation of the synthetic RKC peptide to CD11b or CD11c. However, this 
domain recognition site by the β2 integrins may also be dependent on the integrin 
heterodimer being engaged. Definition of the precise domain binding structure on the 
I-domain of β2 integrins will help address these issues. Diamond et al. (1993) have 
previously produced α subunit chimeras for β
2 
integrins which have successfully 
transfected COS cells. In the same way, chimeras could be produced for CD11b and 
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CD11c α subunits for use in QCM experiments as well as ELISA experiments such as 
those carried out in this dissertation. Nevertheless, the data from ELISA and flow 
cytometry experiments are relatively consistent showing that sCD23 proteins bind the 
αI-domains of CD11b and CD11c via an RKC motif. 
 
The structure–function relationships of the CD23 protein are increasingly well 
understood and demonstrate that there is considerable functional flexibility in the 
protein, which is regulated by specific interaction surfaces, single key residues or the 
oligomeric state of the protein. The validity of CD23 as a target for therapeutic 
intervention is thus clear. Therefore, if we are able to determine the exact surface 
interactions between CD23 and CD11, then it would be possible to design new 
treatments that use a similar approach to inhibit IgE binding to its receptor. For 
instance, developing small molecule ligands that will (partially or even completely) 
inhibit the CD23-CD11 interaction for treatment of chronic inflammatory disease.  
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8. Addendum 
 
8.1 Addendum A: 
 
 
Figure A1: Structural contexts of the CD23 RKC motif (Borland et al., 2007). Structural data files 
for the NMR structure of derCD23 [1T8C (Hibbert et al., 2005)] and the crystal structures of calcium-
free and calcium bound sCD23 [2H2R and 2H2T, respectively (Wurzburg et al., 2006)] were acquired 
from the Brookhaven protein data base, and images were generated using the PyMOL software suite 
(W. L. DeLano (2002) PyMOL, DeLano Scientific, San Carlos, CA). A) The position of the IgE (blue), 
CD21 (red), and αVβ5 (yellow) binding sites on the 1T8C NMR derCD23 structure (Hibbert et al., 
2005) as a surface model. B) Comparison of the derCD23 and 2H2R Ca
2+
- free sCD23 structures 
(Wurzburg et al., 2006), with Arg
172
 (red) and Lys
173
 (blue) highlighted and the positions of the 
extended side chains shown in panels ii and iv. C) Comparison (as a ribbon diagram) of twenty 
individual NMR structures close to the RKC motif (Hibbert et al., 2005); the individual orientations of 
Arg
172
, Lys
173
, and Cys
174
 are illustrated as sticks. D) RKC motif in detail, superimposing the derCD23 
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(1T8C) structure as gray sticks with the Ca
2+
- free sCD23 structure (2H2R) as blue sticks. E) 
Orientation of the RKC motif in sCD23 structures with calcium either bound (yellow sticks) or free 
(blue sticks) [Wurzburg et al., 2006]. 
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8.2 Addendum B: 
 
   1) CD23                                                                2) peptide FQRKCYYFG 
    
   3) Fibrinogen  
                          
 
Figure B1: Flow cytometry profiles of U937 cells expressing  CD11b and immunostained with a 
mAb to the CD11b I-domain (CBRM1/5). For each histogram the orange line in each panel represents 
differentiated U937 cells pre-incubated with CBRM1/5 followed by incubation with the relative 
protein/peptide. The coloured line in each panel represents the relative protein or ligand incubated with 
differentiated U937 cells in the absence of CBRM1/5. Data are representative of 1 experiment performed 
in duplicate representative of 2 others. 
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